EXECUTION COPY
================================================================================
AGREEMENT AND PLAN OF MERGER
dated as of August 5, 2003
by and between
aaiPharma Inc.,
CIMA LABS INC.,
SCARLET HOLDING CORPORATION,
SCARLET MERGERCO, INC.
and
CRIMSON MERGERCO, INC.
================================================================================
TABLE OF CONTENTS
Page
----
ARTICLE I
DEFINITIONS; INTERPRETATION
1.01 Definitions..............................................................................................2
1.02 Interpretation..........................................................................................11
ARTICLE II
THE MERGERS
2.01 The Mergers.............................................................................................12
2.02 Closing.................................................................................................12
2.03 Effective Time..........................................................................................12
2.04 Effects of the Mergers..................................................................................13
2.05 Certificates of Incorporation and By-laws...............................................................13
2.06 Board of Directors and Officers.........................................................................14
ARTICLE III
CONSIDERATION; EXCHANGE PROCEDURES
3.01 Consideration; Effect on Capital Stock of aaiPharma and S MergerCo......................................14
3.02 Consideration; Effect on Capital Stock of CIMA and C MergerCo...........................................15
3.03 Holding Company Common Stock............................................................................16
3.04 Certain Adjustments.....................................................................................16
3.05 Exchange Procedures.....................................................................................16
3.06 Distributions with Respect to Unexchanged Shares........................................................17
3.07 Further Ownership Rights................................................................................18
3.08 No Fractional Shares of HoldCo Common Stock.............................................................18
3.09 Termination of Exchange Fund............................................................................19
3.10 No Liability............................................................................................19
3.11 Investment of the Exchange Fund.........................................................................19
3.12 Lost Certificates.......................................................................................19
3.13 Withholding Rights......................................................................................20
3.14 Further Assurances......................................................................................20
3.15 Stock Transfer Books....................................................................................20
3.16 aaiPharma Stock Options.................................................................................21
3.17 CIMA Stock Options......................................................................................22
3.18 Reservation of Shares for Stock Options.................................................................23
i
ARTICLE IV
CONDUCT OF BUSINESS PENDING MERGERS
4.01 Forbearances............................................................................................23
ARTICLE V
REPRESENTATIONS AND WARRANTIES
5.01 Disclosure Letters......................................................................................26
5.02 Standard................................................................................................27
5.03 Representations and Warranties of CIMA and aaiPharma....................................................27
5.04 Representations and Warranties With Respect to Holding Company and Subsidiaries.........................43
ARTICLE VI
COVENANTS
6.01 Reasonable Best Efforts.................................................................................43
6.02 Registration Statement; Joint Proxy Statement; Stockholder Approvals....................................44
6.03 Acquisition Proposals...................................................................................48
6.04 Holding Company Board and Officers......................................................................50
6.05 Press Releases; Public Announcements....................................................................51
6.06 Access; Information.....................................................................................52
6.07 Takeover Laws and Rights Plans..........................................................................52
6.08 Nasdaq Listing..........................................................................................53
6.09 Regulatory and Third Party Approvals....................................................................53
6.10 Indemnification.........................................................................................55
6.11 Benefit Plans...........................................................................................56
6.12 Notification of Certain Matters.........................................................................57
6.13 Exemption from Liability Under Section 16(b)............................................................58
6.14 Affiliate Notices.......................................................................................58
6.15 Rights Plans............................................................................................59
6.16 Control of Other Party's Business.......................................................................59
6.17 Treasury Regulation Statement...........................................................................59
ARTICLE VII
CONDITIONS TO THE MERGERS
7.01 Conditions to Each Party's Obligation to Effect the Mergers.............................................59
7.02 Conditions to CIMA's Obligation.........................................................................60
7.03 Conditions to aaiPharma's Obligation....................................................................61
ii
ARTICLE VIII
TERMINATION
8.01 Termination.............................................................................................62
8.02 Effect of Termination and Abandonment...................................................................64
ARTICLE IX
MISCELLANEOUS
9.01 Survival................................................................................................66
9.02 Waiver; Amendment.......................................................................................66
9.03 Counterparts............................................................................................66
9.04 Governing Law...........................................................................................66
9.05 Expenses................................................................................................67
9.06 Notices.................................................................................................67
9.07 Entire Understanding; No Third Party Beneficiaries......................................................68
9.08 Severability............................................................................................68
9.09 Submission to Jurisdiction; Waivers.....................................................................68
9.10 Enforcement.............................................................................................69
9.11 Acknowledgment..........................................................................................69
9.12 Assignment..............................................................................................69
Exhibits
Annex 1 Form of Holding Company Certificate of Incorporation
Annex 2 Form of
aaiPharma Inc. Certificate of Incorporation
Annex 3 Form of CIMA LABS INC. Certificate of Incorporation
Annex 4 Form of Holding Company By-Laws
Exhibit 2.06(d)(i) Board of Directors of aaiPharma Surviving Corporation
Exhibit 2.06(d)(ii) Board of Directors of CIMA Surviving Corporation
Exhibit 6.04(c) Officers of Holding Company at Effective Time
Exhibit 7.01(g) Forms of Tax Representation Letters
iii
AGREEMENT AND PLAN OF MERGER
THIS
AGREEMENT AND PLAN OF MERGER, dated as of August 5, 2003, is
entered into by and between
aaiPharma Inc., a
Delaware corporation
("aaiPharma"), CIMA LABS INC., a
Delaware corporation ("CIMA"), SCARLET HOLDING
CORPORATION, a
Delaware corporation and a direct, wholly owned subsidiary of
aaiPharma ("Holding Company"), SCARLET MERGERCO, INC., a
Delaware corporation
and a direct, wholly owned subsidiary of Holding Company ("S MergerCo"), and
CRIMSON MERGERCO, INC., a
Delaware corporation and a direct, wholly owned
subsidiary of Holding Company ("C MergerCo").
BACKGROUND STATEMENT
A. The Proposed Transaction. The parties intend to effect a strategic
business combination in a merger of equals transaction. Upon the terms and
subject to the conditions of this Agreement, Holding Company will acquire all of
the capital stock of each of aaiPharma and CIMA through the merger of S MergerCo
with and into aaiPharma (the "aaiPharma Merger"), with aaiPharma as the
surviving corporation, and the merger of C MergerCo with and into CIMA (the
"CIMA Merger" and, together with the aaiPharma Merger, the "Mergers"), with CIMA
as the surviving corporation. As a result of the Mergers, the respective holders
of capital stock of CIMA and aaiPharma will collectively own all of the
outstanding shares of capital stock of Holding Company. In connection with the
Mergers, Holding Company will change its name to "aaiPharma/Cima Inc.", or such
name as the parties may otherwise agree, and Holding Company will locate its
principal executive office in Wilmington, North Carolina.
B. Board Determinations. The Boards of Directors of aaiPharma, S
MergerCo and Holding Company have each approved the aaiPharma Merger in
accordance with applicable law, upon the terms and subject to the conditions set
forth herein. The Boards of Directors of CIMA, C MergerCo and Holding Company
have each approved the CIMA Merger in accordance with applicable law, upon the
terms and subject to the conditions set forth herein. The respective Boards of
Directors of aaiPharma, CIMA, Holding Company, S MergerCo and C MergerCo have
each determined that the Mergers and the other transactions contemplated hereby
are consistent with, and will further, their respective business strategies and
goals, and are advisable and in the best interests of their respective
stockholders and, therefore, have approved the Mergers to which they are a
party, this Agreement and the plans of merger contained in this Agreement.
C. Stockholder Voting Agreements. As a condition to and inducement to
CIMA's willingness to enter into this Agreement, simultaneously with the
execution of this Agreement, certain stockholders of aaiPharma are entering into
Stockholder Voting Agreements with CIMA (the "aaiPharma Voting Agreements").
Similarly, as a condition to and inducement to aaiPharma's willingness to enter
into this Agreement, simultaneously with the execution of this Agreement,
certain stockholders of CIMA are entering into Stockholder Voting Agreements
with aaiPharma (the "CIMA Voting Agreements").
D. Intended Tax Treatment. The parties intend that each of the Mergers
be treated as a reorganization, and to adopt this Agreement as a plan of
reorganization with respect to both Mergers, within the meaning of Section
368(a) of the Internal Revenue Code of 1986, as amended (the "Code") and the
Treasury Regulations promulgated thereunder (the "Treasury
1
Regulations") and that the Mergers, taken together, shall qualify as an exchange
described in Section 351 of the Code and the Treasury Regulations.
STATEMENT OF AGREEMENT
The parties hereto agree as follows:
ARTICLE I
DEFINITIONS; INTERPRETATION
1.01 Definitions. This Agreement uses the following definitions:
"aaiPharma" has the meaning assigned in the preamble.
"aaiPharma Board" means the Board of Directors of aaiPharma.
"aaiPharma Certificate of Merger" has the meaning assigned in Section
2.03.
"aaiPharma Certificates" has the meaning assigned in Section 3.01(c).
"aaiPharma Common Stock" means the common stock, par value $0.001 per
share, of aaiPharma.
"aaiPharma Exchange Ratio" has the meaning assigned in Section 3.01(a).
"aaiPharma Insiders" means those officers and directors of aaiPharma
who are subject to the reporting requirements of Section 16(a) of the Exchange
Act and who are listed in the Section 16 Information.
"aaiPharma Meeting" has the meaning assigned in Section 6.02(e).
"aaiPharma Merger" has the meaning assigned in the Background
Statement.
"aaiPharma Merger Consideration" has the meaning assigned in Section
3.01(a).
"aaiPharma Preferred Stock" means the preferred stock, $0.001 per
share, of aaiPharma.
"aaiPharma Recommendation" has the meaning assigned in Section 6.02(e).
"aaiPharma Stock" means the aaiPharma Common Stock and the aaiPharma
Preferred Stock.
"aaiPharma Stockholder Approval" has the meaning assigned in Section
5.03(f).
"aaiPharma Stock Option" has the meaning assigned in Section 3.16(a).
2
"aaiPharma Stock Plans" means the
aaiPharma Inc. 1997 Stock Option
Plan, the
aaiPharma Inc. 1996 Stock Option Plan, the
aaiPharma Inc. 1995 Stock
Option Plan and the
aaiPharma Inc. 2000 Stock Option Plan for Non-Employee
Directors.
"aaiPharma Surviving Corporation" has the meaning assigned in Section
2.01(a).
"Acquisition Proposal," means any offer or proposal with respect to an
Acquisition Transaction.
"Acquisition Transaction," with respect to either CIMA or aaiPharma,
means any (i) merger, consolidation, business combination or similar transaction
involving such party or any of its Significant Subsidiaries, (ii) sale, lease or
other disposition directly or indirectly by merger, consolidation, business
combination, share exchange, joint venture or otherwise of assets of such party
or its Subsidiaries representing 15% or more of the consolidated assets of such
party and its Subsidiaries, (iii) issuance, sale or other disposition of
(including by way of merger, consolidation, business combination, share
exchange, joint venture or any similar transaction) securities (or Rights with
respect to such securities) representing 15% or more of the voting power of such
party (other than a public offering of common stock not in connection with a
merger, consolidation, business combination, share exchange, joint venture or
similar transaction), (iv) transaction (including a tender or exchange offer) in
which any Person shall acquire beneficial ownership, or the right to acquire
beneficial ownership, or any "group" (as defined in Rule 13d-5(b)(1) under the
Exchange Act) shall have been formed which beneficially owns or has the right to
acquire beneficial ownership of, 15% or more of the outstanding voting capital
stock of such party (other than one or more bona fide underwriters in connection
with a public offering of common stock not in connection with a merger,
consolidation, business combination, share exchange, joint venture or similar
transaction) or (v) any combination of the foregoing (other than the Mergers).
"Additional Directors" has the meaning assigned in Section 6.04(b).
"Affiliate" means an "affiliate" within the meaning of Rule 12b-2 of
the Exchange Act.
"Agreement" means this Agreement, as amended or modified from time to
time in accordance with its terms.
"Benefit Arrangement" means with respect to each of aaiPharma,
aaiPharma's Subsidiaries and CIMA, each:
(i) "employee benefit plan" (within the meaning of Section 3(3) of
ERISA);
(ii) stock purchase, stock option or other form of incentive
compensation plan;
(iii) severance, parachute, change-in-control, fringe benefit,
bonus, incentive, worker's compensation, disability benefit,
supplemental unemployment benefit, vacation benefit,
retirement benefit, life, health, or accident benefit, or
deferred compensation plan;
(iv) paid time off benefits arrangement; and
3
(v) other employee benefit plan, agreement, program, policy,
commitment or other arrangement (whether written or oral),
whether or not subject to ERISA,
both:
(A) under which any of its current or former employees, the
current or former employees of its Subsidiaries, or any of
their respective ERISA Affiliates, or any of its current or
former officers or directors or those of its Subsidiaries, or
their respective ERISA Affiliates has any present or future
right to benefits; and
(B) which is sponsored, maintained by or contributed to by it, any
of its Subsidiaries, or any of their respective ERISA
Affiliates, or under which it, any of its Subsidiaries, or any
of their respective ERISA Affiliates has had or has any
present or future liability or obligation to contribute.
"Benefit Plan" and "Benefit Plans" have the meanings assigned in
Section 5.03(u)(1).
"Board Designees" have the meaning assigned in Section 6.04(a).
"Business Day" means any day on which banks are not required or
authorized to close in the City of Charlotte, North Carolina or the City of
Minneapolis, Minnesota.
"C MergerCo" has the meaning assigned in the preamble.
"C MergerCo Common Stock" means the common stock, par value $0.01 per
share, of C MergerCo.
"Certificates" has the meaning assigned in Section 3.05(b).
"Certificates of Merger" has the meaning assigned in Section 2.03.
"Change" has the meaning assigned in Section 6.02(e).
"Change in the CIMA Recommendation" has the meaning assigned in Section
6.02(f).
"Change in the aaiPharma Recommendation" has the meaning assigned in
Section 6.02(e).
"CIMA" has the meaning assigned in the preamble.
"CIMA Board" means the Board of Directors of CIMA.
"CIMA Certificate of Merger" has the meaning assigned in Section 2.03.
"CIMA Certificates" has the meaning assigned in Section 3.02(c).
"CIMA Common Stock" means the common stock, par value $0.01 per share,
of CIMA.
"CIMA Exchange Ratio" has the meaning assigned in Section 3.02(a).
4
"CIMA Insiders" means those officers and directors of CIMA who are
subject to the reporting requirements of Section 16(a) of the Exchange Act and
who are listed in the Section 16 Information.
"CIMA Meeting" has the meaning assigned in Section 6.02(f).
"CIMA Merger" has the meaning assigned in the Background Statement.
"CIMA Merger Consideration" has the meaning assigned in Section
3.02(a).
"CIMA Preferred Stock" means the preferred stock, $0.01 par value per
share, of CIMA.
"CIMA Recommendation" has the meaning assigned in Section 6.02(f).
"CIMA Rights" means rights to purchase shares of CIMA Stock issued
under the CIMA Rights Agreement.
"CIMA Rights Agreement" means the Amended and Restated Rights
Agreement, dated as of June 26, 2001, between CIMA and Xxxxx Fargo Bank
Minnesota, N.A., as Rights Agent.
"CIMA Stock" means the CIMA Common Stock and the CIMA Preferred Stock.
"CIMA Stockholder Approval" has the meaning assigned in Section
5.03(f).
"CIMA Stock Option" has the meaning assigned in Section 3.17(a).
"CIMA Stock Plans" means the CIMA LABS INC. 2001 Stock Incentive Plan,
as amended, the CIMA LABS INC. Equity Incentive Plan, as amended and restated,
the CIMA LABS INC. 1994 Directors' Stock Option Plan, as amended, the CIMA LABS
INC. Non-Employee Directors' Fee Option Grant Program as amended, and the CIMA
Stock Purchase Plan.
"CIMA Stock Purchase Plan" means the CIMA LABS INC. Employee Stock
Purchase Plan.
"CIMA Surviving Corporation" has the meaning assigned in Section
2.01(b).
"Closing" has the meaning assigned in Section 2.02.
"Closing Date" has the meaning assigned in Section 2.02.
"Code" has the meaning assigned in the Background Statement.
"Competing Transaction," with respect to either CIMA or aaiPharma,
means any (i) merger, consolidation, business combination or similar transaction
involving such party or any of its Significant Subsidiaries pursuant to which
the stockholders of such party immediately prior to such transaction would own
less than 70% of the voting power of the entity surviving or resulting from such
transaction (or the ultimate parent entity thereof), (ii) sale, lease or other
disposition directly or indirectly by merger, consolidation, business
combination, share
5
exchange, joint venture or otherwise of assets of such party or its Subsidiaries
representing 30% or more of the consolidated assets of such party and its
Subsidiaries, (iii) issuance, sale or other disposition of (including by way of
merger, consolidation, business combination, share exchange, joint venture or
any similar transaction) securities (or Rights with respect to such securities)
representing 30% or more of the voting power of such party (other than a public
offering of common stock not in connection with a merger, consolidation,
business combination, share exchange, joint venture or similar transaction),
(iv) transaction (including a tender or exchange offer) in which any Person
shall acquire beneficial ownership, or the right to acquire beneficial
ownership, or any "group" (as defined in Rule 13d-5(b)(1) under the Exchange
Act) shall have been formed which beneficially owns or has the right to acquire
beneficial ownership of, 30% or more of the outstanding voting capital stock of
such party (other than one or more bona fide underwriters in connection with a
public offering of common stock not in connection with a merger, consolidation,
business combination, share exchange, joint venture or similar transaction) or
(v) any combination of the foregoing (other than the Mergers).
"Confidentiality Agreement" has the meaning assigned in Section
6.06(b).
"Constituent Documents" means the articles or certificate of
incorporation and by-laws of a corporation, the certificate of partnership and
partnership agreement of a general or limited partnership, the certificate of
formation and limited liability company agreement of a limited liability
company, the trust agreement of a trust and the comparable documents of other
entities.
"Continued Employee" means each individual employed by CIMA, aaiPharma
or any of their respective Subsidiaries immediately before the Effective Time
who continues to be employed by Holding Company, CIMA Surviving Corporation,
aaiPharma Surviving Corporation or any of their Subsidiaries immediately after
the Effective Time.
"Costs" has the meaning assigned in Section 6.10(a).
"DGCL" means the General Corporation Law of the State of
Delaware.
"Disclosure Letter" has the meaning assigned in Section 5.01.
"DOJ" has the meaning assigned in Section 5.03(o).
"Effective Time" has the meaning assigned in Section 2.03.
"Employee" and "Employees" have the meanings assigned in Section
5.03(u)(1).
"Environmental Law" has the meaning assigned in Section 5.03(p)(3).
"ERISA" means the Employee Retirement Income Security Act of 1974, as
amended.
"ERISA Affiliate" means any entity which is or at any relevant time was
a member of a "controlled group of corporations" with, under "common control"
with, or a member of an "affiliates service group" with, any Person, as defined
in Section 414(b), (c), (m) or (o) of the Code, or under "common control" with
it, within the meaning of Section 4001(b)(1) of ERISA.
6
"Exchange Act" means the Securities Exchange Act of 1934, as amended,
and the rules and regulations thereunder.
"Exchange Agent" has the meaning assigned in Section 3.05(a).
"Exchange Fund" has the meaning assigned in Section 3.05(a).
"Expenses" means all reasonable, documented, out-of-pocket fees and
expenses (including fees and expenses payable to all investment banking firms
and other Persons, and their respective agents and counsel, for financial
advice, fairness opinions or other advice with respect to the structuring of the
transactions contemplated hereby, and all fees of counsel, accountants, experts
and consultants to CIMA or aaiPharma, as the case may be, all printing and
advertising expenses, and all fees payable to Governmental Authorities or to
third parties in connection with obtaining Requisite Regulatory Approvals or
consents necessary or advisable in connection with the Mergers) actually
incurred by aaiPharma or CIMA, as the case may be, or on their behalf, in
connection with the negotiation, preparation, execution and performance of this
Agreement and the transactions contemplated hereby.
"Former Superior Proposal" has the meaning assigned in Section 6.03(d).
"GAAP" means United States generally accepted accounting principles.
"Governmental Authority" means any national, federal, regional, state,
provincial, local, foreign or other governmental authority or instrumentality,
legislative body, court, administrative agency, regulatory body, commission or
instrumentality, including any multinational authority having governmental or
quasi-governmental powers, or any industry self-regulatory authority.
"Hazardous Substances" has the meaning assigned in Section 5.03(p)(4).
"Holding Company" has the meaning assigned in the preamble.
"HoldCo By-Laws" has the meaning assigned in Section 2.05(d).
"HoldCo Charter" has the meaning assigned in Section 2.05(a).
"HoldCo Common Stock" means the common stock, par value $0.01 per
share, of Holding Company.
"Holding Company Board" means the Board of Directors of Holding
Company.
"HSR Act" means the Xxxx-Xxxxx-Xxxxxx Antitrust Improvements Act of
1976, as amended, and the rules and regulations thereunder.
"Indemnified Party" has the meaning assigned in Section 6.10(a).
"Independent Director" shall mean a member of the CIMA Board or the
aaiPharma Board who would be considered an "independent director" eligible to
serve on the audit committee of the Holding Company Board after the Effective
Time, as such eligibility is
7
determined under Nasdaq Proposed Rule 4350(d)(2)(A) as set forth in SEC Release
No. 34-47516 (March 17, 2003).
"Intellectual Property Rights" shall mean intellectual property rights
arising from or in respect to the following: (i) fictional business names, trade
names, trademarks and service marks, logos, Internet domain names, and general
intangibles of a like nature (collectively, "Marks"); (ii) patents and
applications therefor, including continuation, divisional, continuation-in-part,
or reissue patent applications and patents issuing thereon (collectively,
"Patents"); (iii) copyrights and registrations and applications therefor
(collectively, "Copyrights") and mask work rights; (iv) know-how, inventions,
discoveries, concepts, methods, processes, designs, formulae, technical data,
drawings, specifications, data bases and other proprietary and confidential
information, including customer lists (collectively, "Trade Secrets"); and (v)
computer programs, including any and all software implementations of algorithms,
models and methodologies, whether in source code or object code, databases and
compilations, flow-charts and other work product used to design, plan, organize
and develop any of the foregoing (collectively, "Software").
"Joint Proxy Statement" has the meaning assigned in Section 6.02(a).
"Joint Proxy Statement/Prospectus" has the meaning assigned in Section
6.02(a).
"Law" means any foreign or domestic law, statute, code, ordinance,
rule, regulation, order, judgment, writ, stipulation, award, injunction, decree
or arbitration award or finding.
"Lease" has the meaning assigned in Section 5.03(l)(1).
"Leased Real Property" has the meaning assigned in Section 5.03(l)(1).
"Liability" has the meaning assigned in Section 5.03(p)(2).
"Lien" means any charge, mortgage, pledge, security interest,
restriction, claim, lien, or encumbrance.
"Material Adverse Effect" means, with respect to aaiPharma or CIMA, any
change, event or effect that:
(a) is, or would reasonably be expected to be, material and adverse to
the financial condition, results of operations or business of such party and its
Subsidiaries, taken as a whole, except, in each case, for any such change, event
or effect resulting from or arising out of (i) changes or developments in (x)
the specialty pharmaceutical industry generally, (y) the financial, banking,
currency or capital markets or the economy in general, or (z) Laws of general
applicability (or interpretations thereof by Governmental Authorities), which
changes or developments in each case do not disproportionately affect such party
in any material respect; (ii) the execution or public announcement of this
Agreement and the transactions contemplated hereby; (iii) any reduction in such
party's stock price or trading volume, in and of itself, (iv) a stockholder
class action litigation arising from allegations of a breach of fiduciary duty
relating to this Agreement; (v) changes in GAAP or regulatory accounting
requirements applicable to specialty pharmaceutical companies generally; (vi)
actions or omissions of a party to this
8
Agreement, taken with the prior written consent of the other party to this
Agreement, in contemplation of the transactions contemplated hereby; or (vii) to
the extent consistent with GAAP, any modifications or changes to valuation
policies or practices, or restructuring charges, in each case taken with the
prior written consent of the other party to this Agreement; or
(b) would be reasonably likely to prevent either Merger.
"Material Contracts" has the meaning assigned in Section 5.03(r)(1).
"Mergers" has the meaning assigned in the Background Statement.
"Nasdaq" shall mean the Nasdaq National Market tier of The Nasdaq Stock
Market.
"OIG" has the meaning assigned in Section 5.03(o).
"other party" means, with respect to aaiPharma, CIMA; and with respect
to CIMA, aaiPharma.
"Owned Intellectual Property" has the meaning assigned in Section
5.03(m).
"Owned Real Property" has the meaning assigned in Section 5.03(k).
"Pension Plan" has the meaning assigned in Section 5.03(u)(2).
"Permits" has the meaning assigned in Section 5.03(q)(1).
"Person" is to be interpreted broadly to include any individual,
corporation, limited liability company, partnership, association, joint-stock
company, business trust or unincorporated organization.
"Previously Disclosed" means information or exceptions set forth by a
party in its Disclosure Letter, provided that (i) such information or exceptions
are set forth by specific subsection references, and (ii) any matter disclosed
in any section of a party's Disclosure Letter shall be considered disclosed for
other sections of such Disclosure Letter, but only to the extent such matter on
its face would reasonably be expected to be pertinent to a particular section of
a party's Disclosure Letter in light of the disclosure made in such section.
"Qualifying Amendment" has the meaning assigned in Section 6.02(d).
"Registration Statement" has the meaning assigned in Section 6.02(a).
"Regulatory Filings" has the meaning assigned in Section 5.03(h)(1).
"Representatives" means, with respect to any Person, such Person's
directors, officers, employees, legal, accounting or financial advisors, agents
or any representatives of such legal, accounting or financial advisors.
"Requisite Regulatory Approvals" has the meaning assigned in Section
6.09(a)(2).
9
"Rights" means, with respect to any Person, securities or obligations
convertible into or exercisable or exchangeable for, or giving any other Person
any right to subscribe for or acquire, or any options, warrants, calls or
commitments relating to, or any stock appreciation right or other instrument the
value of which is determined in whole or in part by reference to the market
price or value of, shares of capital stock of such first Person.
"S MergerCo" has the meaning assigned in the preamble.
"S MergerCo Common Stock" means the common stock, par value $0.01 per
share, of S Merger Co.
"SEC" means the United States Securities and Exchange Commission.
"Secretary of State" means the Secretary of State of the State of
Delaware.
"Section 16 Information" means information regarding the aaiPharma
Insiders and CIMA Insiders, the number of shares of aaiPharma Common Stock held
or to be held by each such aaiPharma Insider expected to be exchanged for HoldCo
Common Stock pursuant to the aaiPharma Merger, the number of shares of CIMA
Common Stock held or to be held by each such CIMA Insider expected to be
exchanged for HoldCo Common Stock pursuant to the CIMA Merger, the number and
description of the options to purchase shares of aaiPharma Common Stock held by
each such aaiPharma Insider and expected to be converted into options to
purchase shares of HoldCo Common Stock in connection with the aaiPharma Merger
and the number and description of the options to purchase shares of CIMA Common
Stock held by each such CIMA Insider and expected to be converted into options
to purchase shares of HoldCo Common Stock in connection with the CIMA Merger.
"Securities Act" means the Securities Act of 1933, as amended, and the
rules and regulations thereunder.
"Selection Committee" has the meaning assigned in Section 6.04.
"Stockholders Meeting" shall mean, with respect to CIMA, the CIMA
Meeting and, with respect to aaiPharma, the aaiPharma Meeting.
"Subsidiary" and "Significant Subsidiary" have the meanings assigned to
those terms in Rule 1-02 of Regulation S-X promulgated by the SEC.
"Superior Proposal," with respect to CIMA or aaiPharma, means an
unsolicited, bona fide written offer or proposal (on its most recently amended
or modified terms, if amended or modified) made by a Person (other than CIMA or
aaiPharma, as applicable, and their Affiliates): (i) to acquire, directly or
indirectly, pursuant to a tender offer, exchange offer, merger, consolidation,
business combination, asset acquisition, stock issuance or other similar
transaction, all or substantially all of the assets of such party or a majority
of the total outstanding voting securities of such party, (ii) on terms that the
Board of Directors of such party concludes in good faith to be more favorable to
its stockholders than the Mergers and the other transactions contemplated by
this Agreement (including any revisions hereto), in each case (A) after
receiving the advice of its financial advisors (who shall be a nationally
recognized
10
investment banking firm), (B) after taking into account the likelihood of
consummation of such transaction on the terms set forth therein (as compared to,
and with due regard for, the terms herein) and (C) after taking into account all
legal (after receiving the advice of outside counsel), financial (including the
financing terms of any such proposal), regulatory and other aspects of such
proposal and any other relevant factors permitted under applicable law, and
(iii) that is, in the good faith judgment of the Board of Directors of such
party, reasonably likely to be completed and financed.
"Superior Proposal Notice" has the meaning assigned in Section
6.03(c)(5).
"Takeover Laws" has the meaning assigned in Section 5.03(z).
"Takeover Provisions" has the meaning assigned in Section 5.03(z).
"Tax" and "Taxes" means all federal, state, local or foreign taxes,
charges, fees, levies or other assessments, however denominated, including all
net income, gross income, gains, gross receipts, sales, use, ad valorem, goods
and services, capital, production, transfer, franchise, windfall profits,
license, withholding, payroll, employment, disability, employer health, excise,
estimated, severance, stamp, occupation, property, environmental, unemployment
or other taxes, custom duties, fees, assessments or charges of any kind
whatsoever, together with any interest and any penalties, additions to tax or
additional amounts imposed by any taxing authority whether disputed or not or
arising before, on or after the Effective Time.
"Tax Returns" means any return, amended return or other report
(including elections, declarations, disclosures, schedules, estimates and
information returns) required to be filed with respect to any Tax.
"Termination Date" has the meaning assigned in Section 8.01(f).
"Treasury Regulations" has the meaning assigned in the Background
Statement.
1.02 Interpretation.
(a) In this Agreement, except as the context may otherwise require,
references:
(1) to the Preamble, Background Statement, Sections, Exhibits,
Annexes or Schedules are to the Preamble to, the Background Statement
or Section of, or Exhibit, Annex or Schedule to, this Agreement;
(2) to this Agreement are to this Agreement, and the Exhibits,
Annexes and Schedules to it, taken as a whole;
(3) to any agreement (including this Agreement), contract,
statute or regulation are to the agreement, contract, statute or
regulation as amended, modified, supplemented or replaced from time to
time (in the case of an agreement or contract, to the extent permitted
by the terms hereof); and to any section of any statute or regulation
are to any successor to the section;
11
(4) to the "transactions contemplated hereby" includes the
transactions provided for in this Agreement (including the Annexes to
it); and
(5) to any Governmental Authority includes any successor to
that Governmental Authority.
(b) The table of contents and article and section headings are for
reference purposes only and do not limit or otherwise affect any of the
substance of this Agreement.
(c) The words "include," "includes" or "including" are to be deemed
followed by the words "without limitation."
(d) The words "herein," "hereof" or "hereunder," and similar terms are
to be deemed to refer to this Agreement as a whole and not to any specific
Section.
(e) This Agreement is the product of negotiation by the parties, having
the assistance of counsel and other advisers. The parties intend that this
Agreement not be construed more strictly against either aaiPharma or CIMA.
ARTICLE II
THE MERGERS
2.01 The Mergers. Upon the terms and subject to satisfaction or waiver
of the conditions set forth in this Agreement, and in accordance with the DGCL,
at the Effective Time:
(a) S MergerCo shall be merged with and into aaiPharma; and following
the aaiPharma Merger, the separate corporate existence of S MergerCo shall cease
and aaiPharma shall continue as the surviving corporation of the aaiPharma
Merger ("aaiPharma Surviving Corporation") and as a wholly owned Subsidiary of
Holding Company; and
(b) C MergerCo shall be merged with and into CIMA; and following the
CIMA Merger, the separate corporate existence of C MergerCo shall cease and CIMA
shall continue as the surviving corporation of the CIMA Merger ("CIMA Surviving
Corporation") and as a wholly owned Subsidiary of Holding Company.
2.02 Closing. The closing of the Mergers (the "Closing") shall take
place in the offices of Xxxxxxxx, Xxxxxxxx & Xxxxxx, P.A., 000 Xxxxx Xxxxx
Xxxxxx, Xxxxx 0000, Xxxxxxxxx, Xxxxx Xxxxxxxx, at 10:00 a.m. on the third
Business Day after satisfaction or waiver (subject to applicable Law) of the
conditions set forth in Article VII, other than those conditions that by their
nature cannot be satisfied until the Closing, but subject to the fulfillment or
waiver of those conditions, unless this Agreement has been theretofore
terminated pursuant to its terms or unless another time or date is agreed to in
writing by the parties hereto (the actual date of the Closing, the "Closing
Date").
2.03 Effective Time. Subject to the provisions of this Agreement, as
soon as practicable on the Closing Date, the parties shall cause the Mergers to
be consummated by filing
12
with the Secretary of State a certificate of merger with respect to the
aaiPharma Merger (the "aaiPharma Certificate of Merger") and a certificate of
merger with respect to the CIMA Merger (the "CIMA Certificate of Merger" and,
together with the aaiPharma Certificate of Merger, the "Certificates of
Merger"), each executed in accordance with the relevant provisions of the DGCL.
The parties shall make all other filings required under the DGCL, and the
Mergers shall become effective at such date and time as aaiPharma and CIMA shall
agree and shall specify in the Certificates of Merger (the time the Mergers
become effective being referred to herein as the "Effective Time"); provided
that (i) such date and time shall be later than the time of filing of the
Certificates of Merger and (ii) both Mergers shall become effective at the same
date and time.
2.04 Effects of the Mergers. The Mergers shall have the effects
prescribed in the applicable provisions of the DGCL and this Agreement. Without
limiting the generality of the foregoing, and subject thereto, at the Effective
Time, (a) (i) all the property, rights, privileges, powers and franchises of
aaiPharma and S MergerCo shall be vested in aaiPharma Surviving Corporation, and
(ii) all debts, liabilities and duties of aaiPharma and S MergerCo shall become
the debts, liabilities and duties of aaiPharma Surviving Corporation and (b) (i)
all the property, rights, privileges, powers and franchises of CIMA and C
MergerCo shall be vested in CIMA Surviving Corporation, and (ii) all debts,
liabilities and duties of CIMA and C MergerCo shall become the debts,
liabilities and duties of CIMA Surviving Corporation.
2.05 Certificates of Incorporation and By-laws.
(a) aaiPharma shall take, and shall cause Holding Company to take, all
requisite action to cause the certificate of incorporation of Holding Company to
be in the form of Annex 1, with such changes as CIMA and aaiPharma may agree
prior to the Effective Time (the "HoldCo Charter") immediately prior to the
Effective Time, until thereafter changed or amended as provided therein or by
applicable Law.
(b) The certificate of incorporation of aaiPharma, as in effect
immediately before the Effective Time, shall be amended in the aaiPharma Merger
to read in its entirety as specified in Annex 2 and, as so amended, shall be the
certificate of incorporation of aaiPharma Surviving Corporation as of the
Effective Time until thereafter changed or amended as provided therein or by
applicable Law.
(c) The certificate of incorporation of CIMA, as in effect immediately
before the Effective Time, shall be amended in the CIMA Merger to read in its
entirety as specified in Annex 3 and, as so amended, shall be the certificate of
incorporation of CIMA Surviving Corporation as of the Effective Time until
thereafter changed or amended as provided therein or by applicable Law.
(d) aaiPharma shall take, and shall cause Holding Company to take, all
requisite action to cause the by-laws of Holding Company to be in the form of
Annex 4, with such changes as CIMA and aaiPharma may agree prior to the
Effective Time (the "HoldCo By-Laws") immediately prior to the Effective Time,
until thereafter changed or amended as provided therein or by applicable Law.
13
(e) The by-laws of S MergerCo, as in effect immediately before the
Effective Time, shall be the by-laws of aaiPharma Surviving Corporation as of
the Effective Time until thereafter changed or amended as provided therein or by
applicable Law. Such bylaws shall not be inconsistent with Section 6.10(b).
(f) The by-laws of C MergerCo, as in effect immediately before the
Effective Time, shall be the by-laws of CIMA Surviving Corporation as of the
Effective Time until thereafter changed or amended as provided therein or by
applicable Law. Such bylaws shall not be inconsistent with Section 6.10(b).
2.06 Board of Directors and Officers.
(a) aaiPharma shall take, and shall cause Holding Company to take, all
requisite action to cause the directors and officers of Holding Company at the
Effective Time to be as aaiPharma and CIMA shall agree pursuant to the covenants
and agreements set forth in Section 6.04.
(b) The Board of Directors of S MergerCo immediately prior to the
Effective Time shall be the Board of Directors of aaiPharma Surviving
Corporation, and the officers of aaiPharma immediately prior to the Effective
Time shall be the officers of aaiPharma Surviving Corporation, in each case,
until the earlier of their respective resignation or removal or until their
respective successors are duly elected and qualified, as the case may be.
(c) The Board of Directors of C MergerCo immediately prior to the
Effective Time shall be the Board of Directors of CIMA Surviving Corporation,
and the officers of CIMA immediately prior to the Effective Time shall be the
officers of CIMA Surviving Corporation, in each case, until the earlier of their
respective resignation or removal or until their respective successors are duly
elected and qualified, as the case may be.
(d) Holding Company shall cause the Persons set forth on Exhibit
2.06(d)(i) to be appointed directors of aaiPharma Surviving Corporation and the
Persons set forth on Exhibit 2.06(d)(ii) to be appointed directors of CIMA
Surviving Corporation, respectively, in each case effective as of immediately
following the Effective Time.
ARTICLE III
CONSIDERATION; EXCHANGE PROCEDURES
3.01 Consideration; Effect on Capital Stock of aaiPharma and S
MergerCo. At the Effective Time, by virtue of the aaiPharma Merger and without
any action on the part of aaiPharma, Holding Company, S MergerCo or any holder
of aaiPharma Common Stock, HoldCo Common Stock or S MergerCo Common Stock:
(a) Each share of aaiPharma Common Stock issued and outstanding
immediately prior to the Effective Time (other than shares of aaiPharma Common
Stock held by aaiPharma or owned by CIMA, Holding Company, S MergerCo or C
MergerCo, all of which shall be canceled as provided in Section 3.01(b)) shall
be converted into the right to receive one (1) (the
14
"aaiPharma Exchange Ratio") validly issued, fully paid and non-assessable share
of HoldCo Common Stock (together with any cash in lieu of fractional shares of
HoldCo Common Stock to be paid pursuant to Section 3.08, the "aaiPharma Merger
Consideration").
(b) Each share of aaiPharma Common Stock held by aaiPharma or owned by
Holding Company, CIMA, S MergerCo or C MergerCo immediately prior to the
Effective Time shall, by virtue of the aaiPharma Merger, cease to be outstanding
and shall be canceled, and no HoldCo Common Stock or other consideration shall
be delivered in exchange therefor.
(c) All shares of aaiPharma Common Stock outstanding immediately prior
to the Effective Time shall cease to be outstanding and shall be canceled and
shall cease to exist, and each holder of a certificate or certificates which
immediately prior to the Effective Time represented any such shares of aaiPharma
Common Stock ("aaiPharma Certificates") shall thereafter cease to have any
rights with respect to such shares of aaiPharma Common Stock, except as provided
herein or by Law, and each aaiPharma Certificate previously representing such
shares shall thereafter represent the right to receive the aaiPharma Merger
Consideration payable in respect of such shares of aaiPharma Common Stock and
any dividends or other distributions to which such holder is entitled to
pursuant to Section 3.06.
(d) Each share of S MergerCo Common Stock issued and outstanding
immediately prior to the Effective Time shall be converted into one validly
issued, fully paid and non-assessable share of common stock, par value $0.001
per share, of aaiPharma Surviving Corporation.
3.02 Consideration; Effect on Capital Stock of CIMA and C MergerCo. At
the Effective Time, by virtue of the CIMA Merger and without any action on the
part of CIMA, Holding Company, C MergerCo or any holder of CIMA Common Stock,
HoldCo Common Stock or C MergerCo Common Stock:
(a) Each share of CIMA Common Stock issued and outstanding immediately
prior to the Effective Time (other than shares of CIMA Common Stock held by CIMA
or owned by aaiPharma, Holding Company, S MergerCo or C MergerCo, all of which
shall be canceled as provided in Section 3.02(b)) shall be converted into the
right to receive 1.3657 (the "CIMA Exchange Ratio") validly issued, fully paid
and non-assessable shares of HoldCo Common Stock (together with any cash in lieu
of fractional shares of HoldCo Common Stock to be paid pursuant to Section 3.08,
the "CIMA Merger Consideration").
(b) Each share of CIMA Common Stock held by CIMA or owned by Holding
Company, aaiPharma, S MergerCo or C MergerCo immediately prior to the Effective
Time shall, by virtue of the CIMA Merger, cease to be outstanding and shall be
canceled, and no HoldCo Common Stock or other consideration shall be delivered
in exchange therefor.
(c) All shares of CIMA Common Stock outstanding immediately prior to
the Effective Time shall cease to be outstanding and shall be canceled and shall
cease to exist, and each holder of a certificate or certificates which
immediately prior to the Effective Time represented any such shares of CIMA
Common Stock ("CIMA Certificates") shall thereafter cease to have any rights
with respect to such shares of CIMA Common Stock, except as provided
15
herein or by Law, and each CIMA Certificate previously representing such shares
shall thereafter represent the right to receive the CIMA Merger Consideration
payable in respect of such shares of CIMA Common Stock and any dividends or
other distributions to which such holder is entitled to pursuant to Section
3.06.
(d) Each share of C MergerCo Common Stock issued and outstanding
immediately prior to the Effective Time shall be converted into one validly
issued, fully paid and non-assessable share of common stock, par value $0.01 per
share, of CIMA Surviving Corporation.
3.03 Holding Company Common Stock. At the Effective Time, each share of
capital stock of Holding Company issued and outstanding immediately prior to the
Effective Time and owned by aaiPharma shall be contributed to Holding Company,
without payment of any consideration therefor, and thereupon retired.
3.04 Certain Adjustments. If, between the date of this Agreement and
the Effective Time, the outstanding shares of HoldCo Common Stock, CIMA Common
Stock or aaiPharma Common Stock shall have been changed into, or exchanged for,
a different number of shares or a different class, by reason of any
reclassification, recapitalization, stock split, split-up, combination or
exchange of shares or a stock dividend or dividend payable in any other
securities shall be declared with a record date within such period, or any
similar event shall have occurred, the aaiPharma Exchange Ratio and the CIMA
Exchange Ratio, each to the extent affected thereby, shall be correspondingly
adjusted to provide to the holders of aaiPharma Common Stock, aaiPharma Stock
Options, CIMA Common Stock and CIMA Stock Options the same economic effect as
contemplated by this Agreement prior to such event.
3.05 Exchange Procedures.
(a) As of the Effective Time, Holding Company shall deposit, or cause
to be deposited, with Wachovia Bank, National Association or, in the event
Wachovia Bank, National Association is unwilling or unable to serve as the
exchange agent, such other commercial bank or trust company of recognized
standing reasonably acceptable to CIMA and aaiPharma (in such capacity, the
"Exchange Agent"), for the respective benefit of the holders of the aaiPharma
Certificates and the CIMA Certificates, for exchange, in accordance with this
Article III, through the Exchange Agent, certificates representing the HoldCo
Common Stock issuable to the respective holders of aaiPharma Certificates and
CIMA Certificates and cash payable pursuant to Section 3.08. Holding Company
agrees to make available, or cause to be made available, to the Exchange Agent,
from time to time as needed, cash sufficient to pay any dividends and other
distributions pursuant to Section 3.06. Any cash and certificates representing
HoldCo Common Stock deposited with the Exchange Agent shall hereinafter be
referred to as the "Exchange Fund." The Exchange Agent shall, pursuant to
irrevocable instructions, deliver out of the Exchange Fund the aaiPharma Merger
Consideration contemplated to be paid for shares of aaiPharma Common Stock
pursuant to this Agreement and the CIMA Merger Consideration contemplated to be
paid for shares of CIMA Common Stock pursuant to this Agreement. Except as
contemplated by Sections 3.06 and 3.08, the Exchange Fund shall not be used for
any other purpose.
16
(b) Promptly after the Effective Time, Holding Company shall cause the
Exchange Agent to mail to each holder of record of a aaiPharma Certificate or a
CIMA Certificate (collectively, the "Certificates") (i) a letter of transmittal
which shall specify that delivery shall be effected, and risk of loss and title
to the Certificates shall pass, only upon proper delivery of the Certificates to
the Exchange Agent, and which letter shall be in customary form and have such
other provisions as Holding Company may reasonably specify (such letter to be
reasonably acceptable to CIMA and aaiPharma prior to the Effective Time) and
(ii) instructions for effecting the surrender of such Certificates in exchange
for the applicable aaiPharma Merger Consideration or CIMA Merger Consideration.
Upon surrender of a Certificate to the Exchange Agent together with such letter
of transmittal, duly executed and completed in accordance with the instructions
thereto, and such other documents as may reasonably be required by the Exchange
Agent, the holder of such Certificate shall be entitled to receive in exchange
therefor (A) one or more shares of HoldCo Common Stock representing, in the
aggregate, the number of whole shares that such holder has the right to receive
pursuant to this Article III (after taking into account all shares of aaiPharma
Common Stock and CIMA Common Stock held by such holder as of the Effective Time)
and (B) a check in the amount equal to the cash that such holder has the right
to receive pursuant to the provisions of this Article III, consisting of cash in
lieu of any fractional shares of HoldCo Common Stock pursuant to Section 3.08
and any dividends or other distributions to which such holder is entitled
pursuant to Section 3.06. No interest will be paid or will accrue on any cash or
other consideration deliverable pursuant to this Article III. In the event of a
transfer of ownership of aaiPharma Common Stock or CIMA Common Stock which is
not registered in the transfer records of aaiPharma or CIMA, as applicable, one
or more certificates of HoldCo Common Stock evidencing, in the aggregate, the
proper number of shares of HoldCo Common Stock and a check in the proper amount
of cash in lieu of any fractional shares of HoldCo Common Stock pursuant to
Section 3.08 and any dividends or other distributions to which such holder is
entitled pursuant to Section 3.06, may be issued with respect to such aaiPharma
Common Stock or CIMA Common Stock, as applicable, to such a transferee if the
Certificates formerly representing such shares of aaiPharma Common Stock or CIMA
Common Stock, as applicable, are presented to the Exchange Agent, accompanied by
all documents required to evidence and effect such transfer and to evidence that
any applicable stock transfer taxes have been paid. Until surrendered as
contemplated by this Section 3.05(b), (1) each aaiPharma Certificate shall be
deemed at any time after the Effective Time to represent only the right to
receive upon such surrender the aaiPharma Merger Consideration payable in
respect of the shares of aaiPharma Common Stock formerly represented by such
aaiPharma Certificate, and any dividends or other distributions to which such
holder is entitled pursuant to Section 3.06 and (2) each CIMA Certificate shall
be deemed at any time after the Effective Time to represent only the right to
receive upon such surrender the CIMA Merger Consideration payable in respect of
the shares of CIMA Common Stock formerly represented by such CIMA Certificate,
and any dividends or other distributions to which such holder is entitled
pursuant to Section 3.06.
3.06 Distributions with Respect to Unexchanged Shares. Whenever a
dividend or other distribution is declared by Holding Company in respect of
HoldCo Common Stock the record date for which is at or after the Effective Time,
that declaration shall include dividends or other distributions in respect of
all shares issuable pursuant to this Agreement. No dividends or other
distributions declared or made in respect of HoldCo Common Stock, with a record
date after the Effective Time, shall be paid to the holder of any unsurrendered
Certificate, and no cash
17
payment in lieu of fractional shares of HoldCo Common Stock shall be paid to any
holder pursuant to Section 3.08, unless and until the holder of such Certificate
shall surrender such Certificate in accordance with this Article III. Subject to
the effect of escheat, Tax or other applicable Laws, following surrender of any
such Certificate, there shall be paid to such holder of shares of HoldCo Common
Stock issuable in exchange therefor, in addition to the appropriate aaiPharma
Merger Consideration or CIMA Merger Consideration, as the case may be, and
without interest, (i) promptly after the time of such surrender, the amount of
dividends or other distributions with a record date after the Effective Time
theretofore paid with respect to such whole shares of HoldCo Common Stock, and
(ii) at the appropriate payment date, the amount of dividends or other
distributions with a record date after the Effective Time but prior to such
surrender and a payment date subsequent to such surrender payable with respect
to such whole shares of HoldCo Common Stock.
3.07 Further Ownership Rights. All shares of HoldCo Common Stock issued
and cash paid upon conversion of shares of aaiPharma Common Stock or CIMA Common
Stock, as the case may be, in accordance with the terms of Article II and this
Article III (including any cash paid pursuant to Section 3.06 or Section 3.08)
shall be deemed to have been issued or paid in full satisfaction of all rights
pertaining to such shares of aaiPharma Common Stock or CIMA Common Stock, as the
case may be.
3.08 No Fractional Shares of HoldCo Common Stock.
(a) No certificates or scrip or shares of HoldCo Common Stock
representing fractional shares of HoldCo Common Stock or book-entry credit of
the same shall be issued upon the surrender for exchange of Certificates and
such fractional share interests will not entitle the owner thereof to vote or to
have any rights of a stockholder of Holding Company or a holder of shares of
HoldCo Common Stock.
(b) Notwithstanding any other provision of this Agreement, each holder
of shares of aaiPharma Common Stock exchanged pursuant to the aaiPharma Merger
who would otherwise have been entitled to receive a fraction of a share of
HoldCo Common Stock (after taking into account all aaiPharma Certificates
delivered by such holder) shall receive, in lieu thereof, cash (without
interest) in an amount equal to the product of (i) such fractional part of a
share of HoldCo Common Stock multiplied by (ii) the closing price for a share of
HoldCo Common Stock on Nasdaq (as reported in The Wall Street Journal (Eastern
Edition) or, if not reported therein, in another authoritative source), on the
first trading day on Nasdaq following the Effective Time. No holder of shares of
aaiPharma Common Stock will be entitled to receive pursuant to this Section 3.08
cash in an amount equal to or greater than the value of one full share of HoldCo
Common Stock.
(c) Notwithstanding any other provision of this Agreement, each holder
of shares of CIMA Common Stock exchanged pursuant to the CIMA Merger who would
otherwise have been entitled to receive a fraction of a share of HoldCo Common
Stock (after taking into account all CIMA Certificates delivered by such holder)
shall receive, in lieu thereof, cash (without interest) in an amount equal to
the product of (i) such fractional part of a share of HoldCo Common Stock
multiplied by (ii) the closing price for a share of HoldCo Common Stock on
Nasdaq (as reported in The Wall Street Journal (Eastern Edition) or, if not
reported therein, in
18
another authoritative source), on the first trading day on Nasdaq following the
Effective Time. No holder of shares of CIMA Common Stock will be entitled to
receive pursuant to this Section 3.08 cash in an amount equal to or greater than
the value of one full share of HoldCo Common Stock.
(d) As promptly as practicable after the determination of the amount of
cash, if any, to be paid to holders of fractional interests, the Exchange Agent
shall so notify Holding Company, and Holding Company shall deposit, or shall
cause the deposit of, such amount with the Exchange Agent and shall cause the
Exchange Agent to forward payments to such holders of fractional interests
subject to and in accordance with the terms hereof.
3.09 Termination of Exchange Fund. Any portion of the Exchange Fund
which remains undistributed to the holders of Certificates for six months after
the Effective Time shall be delivered to Holding Company or otherwise on the
instruction of Holding Company, and any holders of the Certificates who have not
theretofore complied with this Article III shall thereafter look only to Holding
Company for the aaiPharma Merger Consideration or the CIMA Merger Consideration,
as the case may be, payable with respect to the shares of aaiPharma Common Stock
or CIMA Common Stock, as the case may be, formerly represented thereby to which
such holders are entitled pursuant to this Article III and any dividends or
distributions with respect to shares of HoldCo Common Stock to which such
holders are entitled pursuant to Section 3.06, in each case, without any
interest thereon. Any such portion of the Exchange Fund remaining unclaimed by
holders of Certificates five years after the Effective Time (or such earlier
date immediately prior to such time as such amounts would otherwise escheat to
or become property of any Governmental Authority) shall, to the extent permitted
by Law, become the property of Holding Company free and clear of any claims or
interest of any Person previously entitled thereto.
3.10 No Liability. None of Holding Company, CIMA, C MergerCo, S
MergerCo, aaiPharma, aaiPharma Surviving Corporation, CIMA Surviving Corporation
or the Exchange Agent shall be liable to any Person in respect of any aaiPharma
Merger Consideration or CIMA Merger Consideration (or dividends or distributions
with respect thereto) from the Exchange Fund delivered to a public official
pursuant to any applicable abandoned property, escheat or similar laws.
3.11 Investment of the Exchange Fund. The Exchange Agent shall invest
any cash included in the Exchange Fund, as directed by Holding Company, on a
daily basis; provided that no such gain or loss thereon shall affect the amounts
payable to the aaiPharma stockholders or the CIMA stockholders pursuant to
Article II and the other provisions of this Article III. Any interest and other
income resulting from such investments shall promptly be paid to Holding Company
upon the termination of the Exchange Fund pursuant to Section 3.09.
3.12 Lost Certificates. If any Certificate shall have been lost, stolen
or destroyed, upon the making of an affidavit of that fact by the Person
claiming such Certificate to be lost, stolen or destroyed and, if required by
Holding Company, the posting by such Person of a bond, in such reasonable amount
as Holding Company may direct, as indemnity against any claim that may be made
against it with respect to such Certificate, the Exchange Agent will pay in
exchange for such lost, stolen or destroyed Certificate the applicable aaiPharma
Merger Consideration or
19
CIMA Merger Consideration, as the case may be, payable with respect to the
shares of aaiPharma Common Stock or CIMA Common Stock, as the case may be,
formerly represented thereby and any unpaid dividends and distributions on
shares of HoldCo Common Stock to which such holders are entitled pursuant to
Section 3.06, deliverable in respect thereof, in each case, without any interest
thereon.
3.13 Withholding Rights. Each of Holding Company, aaiPharma Surviving
Corporation, CIMA Surviving Corporation and the Exchange Agent shall be entitled
to deduct and withhold from the consideration otherwise payable pursuant to this
Agreement to any holder of shares of aaiPharma Common Stock or CIMA Common Stock
or any holder of aaiPharma Stock Options, CIMA Stock Options or any other equity
rights in aaiPharma or CIMA, such amounts as it is required to deduct and
withhold with respect to the making of such payment under the Code and the
Treasury Regulations or any provision of state, local or foreign Tax Law. To the
extent that amounts are so withheld by Holding Company, aaiPharma Surviving
Corporation, CIMA Surviving Corporation or the Exchange Agent, as the case may
be, such withheld amounts shall be treated for all purposes of this Agreement as
having been paid to the holder of the shares of aaiPharma Common Stock or CIMA
Common Stock, or the holder of aaiPharma Stock Options, CIMA Stock Options or
any other equity rights in aaiPharma or CIMA, as applicable, in each case, in
respect of which such deduction and withholding was made by Holding Company,
aaiPharma Surviving Corporation, CIMA Surviving Corporation or the Exchange
Agent, as the case may be.
3.14 Further Assurances.
(a) After the Effective Time, the officers and directors of aaiPharma
Surviving Corporation shall be authorized to execute and deliver, in the name
and on behalf of aaiPharma or S MergerCo, any deeds, bills of sale, assignments
or assurances and to take and do, in the name and on behalf of aaiPharma or S
MergerCo, any other actions and things to vest, perfect or confirm of record or
otherwise in aaiPharma Surviving Corporation any and all right, title and
interest in, to and under any of the rights, properties or assets acquired or to
be acquired by aaiPharma Surviving Corporation as a result of, or in connection
with, the aaiPharma Merger.
(b) After the Effective Time, the officers and directors of CIMA
Surviving Corporation shall be authorized to execute and deliver, in the name
and on behalf of CIMA or C MergerCo, any deeds, bills of sale, assignments or
assurances and to take and do, in the name and on behalf of CIMA or C MergerCo,
any other actions and things to vest, perfect or confirm of record or otherwise
in CIMA Surviving Corporation any and all right, title and interest in, to and
under any of the rights, properties or assets acquired or to be acquired by CIMA
Surviving Corporation as a result of, or in connection with, the CIMA Merger.
3.15 Stock Transfer Books. The stock transfer books of aaiPharma and
CIMA shall be closed immediately upon the Effective Time; and thereafter, there
shall be no further registration of transfers of shares of aaiPharma Common
Stock or CIMA Common Stock outstanding as of the Effective Time on the records
of aaiPharma or CIMA, as the case may be. On or after the Effective Time, (i)
any aaiPharma Certificates presented to the Exchange Agent or Holding Company
for any reason shall be converted into the right to receive the aaiPharma Merger
Consideration with respect to the shares of aaiPharma Common Stock formerly
represented
20
thereby, including any cash in lieu of fractional shares of HoldCo Common Stock
to which the holders thereof are entitled pursuant to Section 3.08 and any
dividends or other distributions to which the holders thereof are entitled
pursuant to Section 3.06, and (ii) any CIMA Certificates presented to the
Exchange Agent or Holding Company for any reason shall be converted into the
right to receive the CIMA Merger Consideration with respect to the shares of
CIMA Common Stock formerly represented thereby, including any cash in lieu of
fractional shares of HoldCo Common Stock to which the holders thereof are
entitled pursuant to Section 3.08 and any dividends or other distributions to
which the holders thereof are entitled pursuant to Section 3.06.
3.16 aaiPharma Stock Options.
(a) Each option to purchase aaiPharma Common Stock (a "aaiPharma Stock
Option") that was granted pursuant to the aaiPharma Stock Plans prior to the
Effective Time, whether or not exercisable at the Effective Time, and which
remains outstanding immediately prior to the Effective Time, shall cease to
represent a right to acquire shares of aaiPharma Common Stock and shall be
appropriately adjusted and converted, at the Effective Time, into an option to
acquire HoldCo Common Stock in accordance with this Section 3.16(a). Each
aaiPharma Stock Option so converted shall continue to have, and be subject to,
the same terms and conditions as were applicable under the aaiPharma Stock
Option (but taking into account any changes thereto provided for in the
aaiPharma Stock Plans or in such option by reason of this Agreement or the
transactions contemplated hereby), and each aaiPharma Stock Option shall be
appropriately adjusted and converted into an option to acquire that number of
shares of HoldCo Common Stock determined by multiplying the number of shares of
aaiPharma Common Stock subject to such aaiPharma Stock Option by the aaiPharma
Exchange Ratio, rounded down, if necessary, to the nearest whole share of HoldCo
Common Stock, at a price per share (rounded up to the nearest cent) equal to the
per share exercise price specified in such aaiPharma Stock Option divided by the
aaiPharma Exchange Ratio; provided, however, that in the case of any aaiPharma
Stock Option to which Section 421 of the Code applies by reason of its
qualification under Section 422 of the Code, the option price, the number of
shares subject to such option and the terms and conditions of exercise of such
option shall be determined in a manner consistent with the requirements of
Section 424(a) of the Code so as not to constitute a "modification" of such
option. Each such converted aaiPharma Stock Option shall remain subject to the
terms and conditions of the aaiPharma Stock Plan pursuant to which such
aaiPharma Stock Option was granted and the agreement evidencing the grant of
such aaiPharma Stock Option. On or prior to the Effective Time, aaiPharma and
Holding Company shall take all actions necessary such that all aaiPharma Stock
Options outstanding prior to the Effective Time under the aaiPharma Stock Plans
are treated in accordance with the immediately preceding sentences.
(b) At the Effective Time, Holding Company shall assume each aaiPharma
Stock Option in accordance with the terms of the aaiPharma Stock Plan under
which it was issued and the stock option agreement by which it is evidenced. As
soon as practicable after the Effective Time, but no later than five (5)
Business Days after the Effective Time, Holding Company shall deliver to the
holders of aaiPharma Stock Options appropriate notices setting forth such
holders' rights pursuant to the aaiPharma Stock Plans (including that, in
connection with the aaiPharma Merger and pursuant to the terms of the aaiPharma
Stock Plans, the aaiPharma Stock Options of such holders have become fully
vested and exercisable) and the agreements evidencing the grants of such
aaiPharma Stock Options shall continue in effect on the same terms and
21
conditions. To the extent permitted by Law, Holding Company shall comply with
the terms of the aaiPharma Stock Plans and shall take such reasonable steps as
are necessary or required by, and subject to the provisions of, such aaiPharma
Stock Plans, to have the aaiPharma Stock Options which qualified as incentive
stock options under Section 421 of the Code prior to the Effective Time continue
to qualify as incentive stock options of Holding Company under Section 421 of
the Code after the Effective Time. With respect to aaiPharma Insiders, where
applicable, Holding Company shall administer the aaiPharma Stock Plans with
respect to assumed aaiPharma Stock Options in a manner consistent with the
exemptions provided by Rule 16b-3 promulgated under the Exchange Act.
3.17 CIMA Stock Options.
(a) Each option to purchase CIMA Common Stock (a "CIMA Stock Option")
that was granted pursuant to the CIMA Stock Plans prior to the Effective Time,
whether or not exercisable at the Effective Time, and which remains outstanding
immediately prior to the Effective Time, shall cease to represent a right to
acquire shares of CIMA Common Stock and shall be appropriately adjusted and
converted, at the Effective Time, into an option to acquire HoldCo Common Stock
in accordance with this Section 3.17(a). Each CIMA Stock Option so converted
shall continue to have, and be subject to, the same terms and conditions as were
applicable under the CIMA Stock Option (but taking into account any changes
thereto provided for in the CIMA Stock Plans or in such option by reason of this
Agreement or the transactions contemplated hereby), and each CIMA Stock Option
shall be appropriately adjusted and converted into an option to acquire that
number of shares of HoldCo Common Stock determined by multiplying the number of
shares of CIMA Common Stock subject to such CIMA Stock Option by the CIMA
Exchange Ratio, rounded down, if necessary, to the nearest whole share of HoldCo
Common Stock, at a price per share (rounded up to the nearest cent) equal to the
per share exercise price specified in such CIMA Stock Option divided by the CIMA
Exchange Ratio; provided, however, that in the case of any CIMA Stock Option to
which Section 421 of the Code applies by reason of its qualification under
Section 422 of the Code, the option price, the number of shares subject to such
option and the terms and conditions of exercise of such option shall be
determined in a manner consistent with the requirements of Section 424(a) of the
Code so as not to constitute a "modification" of such option. Each such
converted CIMA Stock Option shall remain subject to the terms and conditions of
the CIMA Stock Plan pursuant to which such CIMA Stock Option was granted and the
agreement evidencing the grant of such CIMA Stock Option. On or prior to the
Effective Time, CIMA and Holding Company shall take all actions necessary such
that all CIMA Stock Options outstanding prior to the Effective Time under the
CIMA Stock Plans are treated in accordance with the immediately preceding
sentences.
(b) At the Effective Time, Holding Company shall assume each CIMA Stock
Option in accordance with the terms of the CIMA Stock Plan under which it was
issued and the stock option agreement by which it is evidenced. As soon as
practicable after the Effective Time, but no later than five (5) Business Days
after the Effective Time, Holding Company shall deliver to the holders of CIMA
Stock Options appropriate notices setting forth such holders' rights pursuant to
the CIMA Stock Plans and the agreements evidencing the grants of such CIMA Stock
Options shall continue in effect on the same terms and conditions. To the extent
permitted by Law, Holding Company shall comply with the terms of the CIMA Stock
Plans and shall take such reasonable steps as are necessary or required by, and
subject to the provisions of, such
22
CIMA Stock Plans, to have the CIMA Stock Options which qualified as incentive
stock options under Section 421 of the Code prior to the Effective Time continue
to qualify as incentive stock options of Holding Company under Section 421 of
the Code after the Effective Time. With respect to CIMA Insiders, where
applicable, Holding Company shall administer the CIMA Stock Plans with respect
to assumed CIMA Stock Options in a manner consistent with the exemptions
provided by Rule 16b-3 promulgated under the Exchange Act.
3.18 Reservation of Shares for Stock Options. Prior to the Closing,
Holding Company shall take all corporate action necessary to reserve for
issuance a sufficient number of shares of HoldCo Common Stock for delivery upon
exercise of aaiPharma Stock Options and CIMA Stock Options after the Effective
Time. Promptly after the Effective Time, but no later than five (5) Business
Days after the Effective Time, Holding Company shall file a registration
statement with the SEC on Form S-8 (or any successor or other appropriate
forms), with respect to the shares of HoldCo Common Stock subject to such
options and shall use commercially reasonable efforts to maintain the
effectiveness of such registration statement or registration statements (and
maintain the current status of the prospectus or prospectuses contained
therein), as well as comply with any applicable state securities Laws, for so
long as such options remain outstanding.
ARTICLE IV
CONDUCT OF BUSINESS PENDING MERGERS
4.01 Forbearances. aaiPharma and CIMA each agrees that from the date
hereof until the Effective Time, except as expressly contemplated by this
Agreement, as required by applicable Law or as Previously Disclosed, without the
prior written consent of the Chief Executive Officer of the other party (which
consent will not be unreasonably withheld or delayed), it will not, and will
cause each of its Subsidiaries not to:
(a) Ordinary Course. (1) Conduct its business and the business of its
Subsidiaries other than in the ordinary and usual course in substantially the
same manner as heretofore conducted, (2) fail to use commercially reasonable
efforts to preserve intact their business organizations, assets (including
Intellectual Property Rights) and goodwill, maintain their rights, licenses,
franchises and authorizations and their existing relations with customers,
suppliers, licensees, licensors and business associates having material business
relationships with them and keep available the services of their current
employees, officers and other managers; provided, that the foregoing shall not
preclude the termination of employees in the ordinary course of business, or (3)
take any action reasonably likely to materially impair its ability to perform
its obligations under this Agreement or to consummate the transactions
contemplated hereby.
(b) Operations. Enter into any new material line of business.
(c) Capital Stock. Issue, authorize for issuance, sell, or otherwise
permit to become outstanding, or dispose of or encumber or pledge, or authorize
or propose the creation of, any additional shares of its capital stock or any
Rights related thereto or any other securities in respect of or in substitution
for shares of its capital stock, other than pursuant to Rights outstanding on
the date of this Agreement pursuant to written agreements or plans.
23
(d) Dividends, Distributions, Repurchases. (1) Make, declare, pay or
set aside for payment any dividend payable in cash, stock or property on, or in
respect of, or declare or make any distribution on, any shares of its capital
stock (other than dividends and distributions from its wholly owned Subsidiaries
to it or another of its wholly owned Subsidiaries) or (2) directly or
indirectly, adjust, split, combine, redeem, reclassify, purchase or otherwise
acquire any shares of its capital stock or any Rights related thereto.
(e) Dispositions; Licenses. Sell, transfer, mortgage, encumber, lease,
license or otherwise dispose of or discontinue any of its assets (including
Intellectual Property Rights), business or properties, except for sales,
transfers, mortgages, encumbrances, licenses or other dispositions or
discontinuances (1) in the ordinary course of business consistent with past
practice or its current strategic plans as disclosed to the other party prior to
the date hereof, including sales of inventory and other current assets and
licenses of Intellectual Property Rights, (2) in a transaction that, together
with other such transactions, is not material to it and its Subsidiaries, taken
as a whole, (3) transactions between it and any of its respective direct or
indirect wholly owned Subsidiaries or between such wholly owned Subsidiaries, or
(4) pursuant to Section 6.09(b).
(f) Acquisitions. Acquire (1) by merging or consolidating with, or by
purchasing a substantial portion of the assets of, or by any other manner, any
business or Person or division thereof, or (2) any assets, except in the case of
each of clause (1) and (2) above, (x) acquisitions of inventory, Intellectual
Property Rights and other items in the ordinary course of business consistent
with past practice, or (y) acquisitions the total consideration for which does
not exceed $10,000,000 individually and $20,000,000 in the aggregate (excluding
contingent milestone and royalty payments not required to be reflected on a
balance sheet as of the date of such acquisition prepared in accordance with
GAAP), provided that any such acquisitions do not present a material risk that
the Closing Date will be materially delayed or that the Requisite Regulatory
Approvals will be more difficult to obtain in any material respect.
(g) Constituent Documents. Amend, alter or modify its Constituent
Documents (or similar governing documents).
(h) Accounting Methods. Implement or adopt any change in its accounting
principles, practices or methods, other than as may be required by GAAP (as
advised by its regular independent accountants) or applicable regulatory
accounting requirements.
(i) Adverse Actions. Notwithstanding anything herein to the contrary,
(1) take, or omit to take, any action that would, or is reasonably likely to,
prevent or impede the aaiPharma Merger or the CIMA Merger from qualifying as a
reorganization within the meaning of Section 368(a) of the Code or the Mergers,
taken together, from qualifying as an exchange described in Section 351 of the
Code or (2) knowingly take, or knowingly omit to take, any action that is
reasonably likely to result in any of the conditions to the Mergers set forth in
Article VII not being satisfied, except as may be required by applicable law or
regulation.
(j) Indebtedness and Investments. (1) Incur any indebtedness for
borrowed money or guarantee or otherwise become contingently liable for any such
indebtedness of another Person, issue or sell any debt securities or warrants or
other rights to acquire any debt securities,
24
guarantee or otherwise become contingently liable for any debt securities of
another Person, enter into any "keep well" or other agreement to maintain any
financial statement condition of another Person or enter into any arrangement
having the economic effect of any of the foregoing, except for borrowings
incurred in the ordinary course of business consistent with past practice and
except for intercompany indebtedness between it and any of its respective direct
or indirect wholly owned Subsidiaries or between such wholly owned Subsidiaries,
or (2) make any loans, advances or capital contributions to, or investments in,
any other Person, other than between it and any of its direct or indirect wholly
owned Subsidiaries or between such Subsidiaries, and other than investments made
in the ordinary course of business consistent with past practice.
(k) Noncompetes; Exclusivity Arrangements. Other than in the ordinary
course of business consistent with past practice or its current strategic plans
as disclosed to the other party prior to the date hereof, enter into any
agreement or arrangement that (1) limits or otherwise restricts it or its
respective Affiliates or any successor thereto, from engaging or competing in
any line of business, field or geographic area or with respect to the
development, license or supply of any pharmaceutical product or delivery device
or (2) provides exclusive rights or licenses to a third Person with respect to
Intellectual Property Rights.
(l) Capital Expenditures. Make or agree to make any new capital
expenditure or expenditures in the aggregate in excess of the amount Previously
Disclosed.
(m) Contracts. (1) Other than in the ordinary course of business, enter
into any agreement or agreements involving aggregate payments by it and its
Subsidiaries that are material to it and its Subsidiaries taken as a whole, or
(2) terminate or materially and adversely amend, modify or change any Material
Contract or waive, release, transfer or assign any material rights or claims
thereunder, other than in the ordinary course of business consistent with past
practice, or (3) enter into any agreement with respect to the voting of its
capital stock or any securities held by it or any of its Subsidiaries.
(n) Taxes. Make any tax election or amend any Tax Return that,
individually or in the aggregate, is reasonably likely to have a material
adverse effect on the tax liability of the Person making the election, or settle
or compromise any material income tax liability.
(o) Litigation. Waive, release, assign, settle, discharge, pay, satisfy
or compromise any material rights or claims, or any material litigation or
arbitration in a manner that is materially adverse to it.
(p) Standstill. Modify, amend or terminate, or waive, release or
assign, any material rights or claims with respect to any confidentiality or
standstill agreement to which it is a party and which relates to a business
combination; provided that if it receives an Acquisition Proposal and its Board
of Directors concludes in good faith, after consultation with a nationally
recognized financial advisor and its outside legal counsel, that such
Acquisition Proposal constitutes a Superior Proposal (and continues to
constitute a Superior Proposal after taking into account any amendment or
modification to this Agreement proposed by the other party hereto during any
three Business Day period referenced in Section 6.03(d)), or its Board of
Directors concludes in good faith, after consultation with a nationally
recognized financial advisor and its outside legal counsel, that there is a
reasonable likelihood that such Acquisition Proposal would
25
reasonably be expected to result in a Superior Proposal, then it may waive
material rights under any standstill provision with the Person making such
Acquisition Proposal to the extent necessary to permit such Person to engage in
discussions or negotiations with it with respect to such Acquisition Proposal.
(q) Affiliate Transactions. Other than in the ordinary course of
business consistent with past practice, engage in any transactions, or enter
into any contract, agreement or arrangement, except as disclosed in filings with
the SEC prior to the date of this Agreement, with any Affiliate (other than any
Subsidiary) or amend, waive or relinquish any rights relating to any such
transaction, contract, agreement or arrangement.
(r) Benefit Arrangements. Except as required by law or contemplated
hereby, enter into, adopt or amend in any material respect or terminate any
Benefit Arrangement, or materially change any actuarial or other assumption used
to calculate funding obligations with respect to any Pension Plan, or change the
manner in which contributions to any Pension Plan are made or the basis on which
such contributions are determined.
(s) Employee Benefits. (1) Except for normal increases in the ordinary
course of business that, in the aggregate, do not materially increase benefits
or compensation expenses, or except as expressly contemplated hereby, increase
the compensation of any director, officer or other key employee or pay or vest
any benefit or amount not expressly required to be paid or vested by a Benefit
Arrangement as in effect on the date of this Agreement to any such Person or (2)
enter into any agreement with respect to, or pay (except as required pursuant to
Benefits Arrangements (including employment contracts) in effect as of the date
of this Agreement), any severance, termination, parachute, change-in-control,
stay bonus or similar compensation or benefit.
(t) Takeover Statutes. Take any action to render inapplicable, or to
exempt any third party from, (1) the provisions of Section 203 of the DGCL, or
(2) any other state Takeover Law or state Law that purports to limit or restrict
business combinations or the ability to acquire or vote shares.
(u) Commitments. Enter into any contract with respect to, or otherwise
agree or commit to do, any of the foregoing.
ARTICLE V
REPRESENTATIONS AND WARRANTIES
5.01 Disclosure Letters. Before entry into this Agreement, CIMA
delivered to aaiPharma a disclosure letter, and aaiPharma delivered to CIMA a
disclosure letter (respectively, each disclosure letter a "Disclosure Letter"),
setting forth, among other things, items the disclosure of which is necessary or
appropriate either in response to an express disclosure requirement contained in
a provision hereof or as an exception to one or more representations or
warranties contained in Section 5.03 or to one or more of its covenants
contained in Articles IV and VI; provided that the mere inclusion of an item in
a Disclosure Letter as an exception to a
26
representation or warranty will not be deemed an admission by a party that such
item is material or was required to be disclosed therein.
5.02 Standard. For all purposes of this Article V, no representation or
warranty of CIMA or aaiPharma contained in Section 5.03 or Section 5.04 (other
than the representations and warranties contained in Sections 5.03(b), 5.03(c),
5.04(a) and 5.04(b), which shall be true in all material respects) will be
deemed untrue, and no party will be deemed to have breached a representation or
warranty as a consequence of the existence of any fact, event or circumstance
unless such fact, circumstance or event, individually or taken together with all
other facts, events or circumstances inconsistent with any representation or
warranty contained in Section 5.03 (read for this purpose without regard to any
individual reference to "materiality" or "material adverse effect"), has had or
is reasonably likely to have a Material Adverse Effect with respect to CIMA or
aaiPharma, as the case may be.
5.03 Representations and Warranties of CIMA and aaiPharma. Except as
Previously Disclosed, CIMA hereby represents and warrants to aaiPharma, and
aaiPharma hereby represents and warrants to CIMA, to the extent applicable, as
follows:
(a) Organization, Standing and Authority. It is a corporation duly
organized, validly existing and in good standing under the laws of the
jurisdiction of its incorporation. It is duly qualified or licensed to do
business and is in good standing in all jurisdictions where its ownership or
leasing of property or assets or its conduct of business requires it to be so
qualified.
(b) CIMA Stock. CIMA represents and warrants to aaiPharma as follows:
(1) The authorized capital stock of CIMA consists of
60,000,000 shares of CIMA Common Stock and 5,000,000 shares of CIMA
Preferred Stock. As of August 1, 2003, (i) 14,484,556 shares of CIMA
Common Stock and no shares of CIMA Preferred Stock were outstanding,
(ii) 1,770,015 shares of CIMA Common Stock were subject to CIMA Stock
Options under the CIMA Stock Plans, (iii) 4,725,617 shares of CIMA
Common Stock were reserved for issuance under the CIMA Stock Plans,
(iv) 619,425 shares of CIMA Common Stock were held in the treasury of
CIMA and (v) ) 5,000,000 shares of CIMA Preferred Stock were designated
as Series A Junior Participating Preferred Stock, none of which were
outstanding. The outstanding shares of CIMA Common Stock have been duly
authorized and are validly issued and outstanding, fully paid and
nonassessable, and subject to no preemptive rights (and were not issued
in violation of any preemptive rights). CIMA has heretofore furnished
aaiPharma complete and correct copies of the Constituent Documents of
CIMA and such Constituent Documents are in full force and effect. CIMA
is not in violation of any of the provisions of its Constituent
Documents.
(2) Except as set forth above, and except for CIMA Stock
Options issued and outstanding, CIMA Rights under the CIMA Rights
Agreement and outstanding purchase rights under the CIMA Stock Purchase
Plan, as of the date of this Agreement, there are no outstanding
subscriptions, options, calls, contracts, commitments, understandings,
restrictions, arrangements, rights or warrants, including any right of
conversion or exchange under any outstanding security, instrument or
other agreement and also
27
including any rights plan or other anti-takeover agreement, obligating
CIMA to issue, deliver or sell, or cause to be issued, delivered or
sold, additional shares of CIMA Common Stock or obligating CIMA or to
grant, extend or enter into any such agreement or commitment. As of the
date hereof, there are no obligations, contingent or otherwise, of CIMA
to (i) repurchase, redeem or otherwise acquire any shares of CIMA
Common Stock except in connection with the exercise of CIMA Stock
Options issued and outstanding or (ii) provide material funds (in the
form of a loan, capital contribution or other investment) to, or make
any material investment in (in the form of a loan, capital contribution
or other investment), or provide any material guarantee with respect to
the obligations of, any Person. There are no outstanding stock
appreciation rights or similar derivative securities or Rights of CIMA.
There are no bonds, debentures, notes or other indebtedness of CIMA
having the right to vote (or convertible into, or exchangeable for,
securities having the right to vote) on any matters on which
stockholders of CIMA may vote. There are no voting trusts, irrevocable
proxies or other agreements or understandings to which CIMA is a party
or is bound with respect to the voting of any shares of CIMA Common
Stock. CIMA has not agreed to register any securities under the
Securities Act or under any state securities law or granted
registration rights to any Person or entity (except rights which have
terminated or expired). CIMA has no outstanding obligations in respect
of prior acquisitions of businesses to pay, in the form of securities,
cash or other property, any portion of the consideration payable to the
seller or sellers in such transaction. As of the date hereof, CIMA has
no Subsidiaries.
(3) CIMA has previously made available to aaiPharma complete
and correct copies of the CIMA Stock Plans, the CIMA Stock Purchase
Plan, and the CIMA Rights Agreement, including, in each case, all
amendments thereto. CIMA has previously made available to aaiPharma a
complete and correct list setting forth as of August 4, 2003, (i) the
number of CIMA Stock Options outstanding (listing grantee and exercise
price), and (ii) the weighted average exercise price for all
outstanding CIMA Stock Options, and complete and correct copies of the
relevant written agreements, including amendments thereto, evidencing
the grant of outstanding CIMA Stock Options.
(c) aaiPharma Stock. aaiPharma represents and warrants to CIMA as
follows:
(1) The authorized capital stock of aaiPharma consists of
100,000,000 shares of aaiPharma Common Stock and 5,000,000 shares of
aaiPharma Preferred Stock. As of August 1, 2003, (i) 27,823,145 shares
of aaiPharma Common Stock and no shares of aaiPharma Preferred Stock
were outstanding, (ii) 6,299,543 shares of aaiPharma Common Stock were
subject to aaiPharma Stock Options granted under the aaiPharma Stock
Plans, (iii) 9,850,691 shares of aaiPharma Common Stock reserved for
issuance under the aaiPharma Stock Plans, and (iv) no shares of
aaiPharma Common Stock were held in the treasury of aaiPharma. The
outstanding shares of aaiPharma Common Stock have been duly authorized
and are validly issued and outstanding, fully paid and nonassessable,
and subject to no preemptive rights (and were not issued in violation
of any preemptive rights). aaiPharma has heretofore furnished CIMA
complete and correct copies of the Constituent Documents of aaiPharma,
its Significant Subsidiaries, Holding Company, S MergerCo and C
MergerCo. Such Constituent Documents are in full force and effect. Each
of aaiPharma, its Significant Subsidiaries, Holding Company, S
28
MergerCo and C MergerCo is not in violation of any of the provisions of
its respective Constituent Documents.
(2) Except as set forth above and except for aaiPharma Stock
Options issued and outstanding, as of the date of this Agreement, there
are no outstanding subscriptions, options, calls, contracts,
commitments, understandings, restrictions, arrangements, rights or
warrants, including any right of conversion or exchange under any
outstanding security, instrument or other agreement and also including
any rights plan or other anti-takeover agreement, obligating aaiPharma
or any Subsidiary of aaiPharma to issue, deliver or sell, or cause to
be issued, delivered or sold, additional shares of aaiPharma Common
Stock or obligating aaiPharma or any Subsidiary of aaiPharma to grant,
extend or enter into any such agreement or commitment. As of the date
hereof, there are no obligations, contingent or otherwise, of aaiPharma
to (i) repurchase, redeem or otherwise acquire any shares of aaiPharma
Common Stock or the capital stock or other equity interests of any
Subsidiary of aaiPharma except in connection with the exercise of
aaiPharma Stock Options issued and outstanding or (ii) provide material
funds (in the form of a loan, capital contribution or other investment)
to, or make any material investment in (in the form of a loan, capital
contribution or other investment), or provide any material guarantee
with respect to the obligations of, any Person other than a Subsidiary.
There are no outstanding stock appreciation rights or similar
derivative securities or Rights of aaiPharma or any of its
Subsidiaries. There are no bonds, debentures, notes or other
indebtedness of aaiPharma having the right to vote (or convertible
into, or exchangeable for, securities having the right to vote) on any
matters on which stockholders of aaiPharma may vote. There are no
voting trusts, irrevocable proxies or other agreements or
understandings to which aaiPharma or any Subsidiary of aaiPharma is a
party or is bound with respect to the voting of any shares of aaiPharma
Common Stock. aaiPharma has not agreed to register any securities under
the Securities Act or under any state securities law or granted
registration rights to any Person or entity (except rights which have
terminated or expired). Neither aaiPharma nor any of its Subsidiaries
has any outstanding obligations in respect of prior acquisitions of
businesses to pay, in the form of securities, cash or other property,
any portion of the consideration payable to the seller or sellers in
such transaction.
(3) aaiPharma has previously made available to CIMA complete
and correct copies of the aaiPharma Stock Plans, including all
amendments thereto. aaiPharma has previously made available to CIMA a
complete and correct list setting forth as of August 1, 2003, (i) the
number of aaiPharma Stock Options outstanding (listing grantee and
exercise price) and (ii) the weighted average exercise price for all
outstanding aaiPharma Stock Options, and complete and correct copies of
the relevant written agreements, including amendments thereto,
evidencing the grant of outstanding aaiPharma Stock Options. As of the
date hereof, aaiPharma has not adopted a stockholder rights plan.
(d) Subsidiaries.
(1) (A) It owns, directly or indirectly, all the outstanding
equity securities of each of its Subsidiaries free and clear of any
Liens, (B) no equity securities of any of its
29
Subsidiaries are or may become required to be issued (other than to it
or its wholly owned Subsidiaries) by reason of any Right or otherwise,
(C) there are no contracts, commitments, understandings or arrangements
by which any of such Subsidiaries is or may be bound to sell or
otherwise transfer any equity securities of any such Subsidiaries
(other than to it or its wholly owned Subsidiaries), (D) there are no
contracts, commitments, understandings, or arrangements relating to its
rights to vote or to dispose of such securities and (E) all the equity
securities of each Subsidiary held by it or its Subsidiaries have been
duly authorized and are validly issued and outstanding, fully paid and
nonassessable and free of preemptive rights. It has no investment in
any other entity other than its Subsidiaries.
(2) Each of its Subsidiaries has been duly organized and is
validly existing in good standing under the laws of the jurisdiction of
its organization, and is duly qualified to do business and in good
standing in all jurisdictions where its ownership or leasing of
property or its conduct of business requires it to be so qualified.
(3) Each of its direct and indirect Subsidiaries in existence
on the date hereof is listed on Section 5.03(d)(3) of its Disclosure
Letter.
(e) Power. It and each of its Subsidiaries has the corporate (or
comparable) power and authority to carry on its business as it is now being
conducted and to own, lease and operate all its properties and assets; and it
and, in the case of aaiPharma, each of Holding Company, C MergerCo and S
MergerCo, has the corporate (or comparable) power and authority to execute,
deliver and perform its obligations under this Agreement and to consummate the
transactions contemplated hereby.
(f) Authority. It and, in the case of aaiPharma, each of Holding
Company, C MergerCo and S MergerCo, has duly authorized and validly executed and
delivered this Agreement. This Agreement and the transactions contemplated
hereby have been approved by its Board of Directors and, in the case of
aaiPharma, by the Holding Company Board and the Board of Directors of each of C
MergerCo and S MergerCo, and duly and validly authorized by all necessary
respective corporate action applicable to it and, in the case of aaiPharma,
applicable to Holding Company, C MergerCo and S MergerCo, subject only (i) in
the case of CIMA, to receipt of the affirmative vote of the holders of a
majority of the outstanding shares of CIMA Common Stock to adopt this Agreement
(the "CIMA Stockholder Approval") and (ii) in the case of aaiPharma, to receipt
of the affirmative vote of the holders of a majority of the outstanding shares
of aaiPharma Common Stock to adopt this Agreement (the "aaiPharma Stockholder
Approval"). This Agreement is its valid and legally binding obligation and, in
the case of aaiPharma, the valid and binding obligation of each of Holding
Company, C MergerCo and S MergerCo, enforceable in accordance with the terms
hereof (except as enforcement may be limited by applicable bankruptcy,
insolvency, reorganization, moratorium, fraudulent transfer and similar laws of
general applicability relating to or affecting creditors' rights or by general
equity principles). CIMA represents to aaiPharma that the CIMA Stockholder
Approval is the only vote of the holders of any class or series of capital stock
of CIMA required to adopt this Agreement. aaiPharma represents to CIMA that the
aaiPharma Stockholder Approval is the only vote of the holders of any class or
series of capital stock of aaiPharma required to adopt this Agreement.
30
(g) Regulatory Approvals; No Defaults.
(1) No consents or approvals of, or filings or registrations
with, or notice to, or authorizations, permits or declarations of, any
Governmental Authority or with any other Person are required to be made
or obtained by it or any of its Subsidiaries in connection with the
execution, delivery or performance by it of this Agreement or to
consummate the Merger except for (A) filing of notices, and expiration
of the related waiting period, under the HSR Act, (B) filings of
applications and notices with, and receipt of approvals or
nonobjections from, the SEC and state securities authorities, the
National Association of Securities Dealers, Inc. and Nasdaq, (D)
filings under the Securities Act and the Exchange Act, (E) receipt of
the applicable stockholder approvals described in Sections 5.03(f) and
6.01(e), and (F) the filing of the Certificates of Merger.
(2) The execution, delivery and performance of this Agreement
and the consummation of the transactions contemplated hereby do not and
will not (A) constitute a breach or violation of, or a default under
(or an event which with notice or lapse of time or both would become a
default), result in any loss of any benefit under, give rise to any
Lien, any acceleration of remedies or any penalty, increase any benefit
or right of termination under, any law, rule or regulation or any
judgment, decree, order, governmental permit or license, or agreement,
indenture, note, mortgage, lease or other contract, commitment,
agreement or instrument to which it or of any of its Subsidiaries or to
which it or any of its Subsidiaries or its or their properties is
subject or bound, (B) conflict with, constitute a breach or violation
of, or a default under, its Constituent Documents or those of any of
its Subsidiaries or (C) assuming that the regulatory consents,
approvals, authorizations, permits and declarations described in
Section 5.03(g)(1) have been obtained and all filings and notifications
described in Section 5.03(g)(1) have been made and the expiration or
termination of related waiting periods, conflict with, violate or
require any consent or approval under any such Law applicable to it or
its Subsidiaries or by which any of its or its Subsidiaries' property
or assets is bound.
(3) As of the date hereof, it is not aware of any reason why
the necessary regulatory approvals and consents will not be received in
order to permit consummation of the Mergers.
(h) Financial Reports and Regulatory Documents.
(1) It has timely filed its Annual Reports on Form 10-K for
the fiscal years ended December 31, 2000, 2001 and 2002, and all other
reports, registration statements, prospectuses, forms, definitive proxy
statements, schedules and documents (including all exhibits,
post-effective amendments and supplements thereto) required to be filed
by it or any of its Subsidiaries subsequent to December 31, 2000 under
the Securities Act or the Exchange Act (collectively, its "Regulatory
Filings"). Each of its Regulatory Filings, as of the date filed, (A)
complied in all material respects as to form with the applicable
requirements under the Securities Act or the Exchange Act, as the case
may be, and (B) did not contain any untrue statement of a material fact
or omit to state a material fact required to be stated therein or
necessary to make the statements therein, in the light of
31
the circumstances under which they were made, not misleading. As of the
date of this Agreement, none of its Subsidiaries is subject to the
periodic reporting requirements of the Exchange Act.
(2) Each of the consolidated financial statements (including
the notes and schedules thereto) contained in the Regulatory Filings
were prepared in accordance with GAAP as in effect on the date of such
report applied on a consistent basis throughout the periods involved
(except as may be indicated therein or in the notes thereto) and each
fairly presented in all material respects the consolidated financial
position, results of operations and cash flows of it and its
consolidated Subsidiaries as at the respective dates thereof for the
periods indicated therein (subject, in the case of unaudited
statements, to normal and recurring year-end adjustments which did not
and would not, individually or in the aggregate, reasonably be expected
to have a Material Adverse Effect on it or its Subsidiaries, taken as a
whole). Its books and records and those of its Subsidiaries have been,
and are being, maintained in all material respects in accordance with
GAAP and any other applicable legal and accounting requirements.
(3) As of the date hereof, except as and to the extent set
forth on its and its consolidated Subsidiaries' consolidated balance
sheet as of December 31, 2002 included in its Annual Report on Form
10-K for the year ended December 31, 2002 (including the notes
thereto), or as set forth on a consolidated balance sheet (including
the notes thereto) included in Regulatory Filings filed with the SEC
after December 31, 2002 and prior to the date of this Agreement,
neither it nor any of its Subsidiaries has any Liabilities of any
nature (whether accrued, absolute, contingent or otherwise) that would
be required to be reflected on a balance sheet or in notes thereto
prepared in accordance with GAAP, except for (i) Liabilities incurred
in the ordinary course of business since December 31, 2002, (ii)
Liabilities which are accrued or reserved against and reflected in the
Company's consolidated financial statements as of December 31, 2002,
and (iii) Liabilities incurred in connection with this Agreement.
(i) Absence of Certain Changes or Events. From December 31, 2002 to the
date hereof (except as disclosed in its Annual Report on Form 10-K for the year
ended December 31, 2002 or in its other Regulatory Filings (including the notes
thereto) filed after December 31, 2002 and prior to the date of this Agreement),
it and its Subsidiaries have conducted their businesses in the ordinary course
of business consistent with past practice and, since December 31, 2002, there
has not been (1) any change, event, or development that, individually or in the
aggregate, has had or would be reasonably likely to have a Material Adverse
Effect with respect to it and its Subsidiaries, taken as a whole, (2) any
change, event or development that would, individually or in the aggregate,
reasonably be expected to prevent it from performing its obligations under this
Agreement or consummating the transactions contemplated hereby, (3) any
declaration, payment or setting aside for payment of any dividend or other
distribution (whether in cash, stock or property or any combination thereof) in
respect of its capital stock, other than dividends or distributions by any of
its wholly owned Subsidiaries to it or another of its wholly owned Subsidiaries,
(4) any sale, transfer, mortgage, pledge or other disposition of (or grant of
permission for any of the foregoing), or encumbrance on, any assets or
properties, real, personal or mixed, material to it and its Subsidiaries taken
as a whole, (5) any increase in any manner of the compensation of any of its or
any of its Subsidiaries' officers, directors or
32
Employees, or entrance into, establishment, amendment or termination of any
Benefits Arrangement with, for or in respect of, any officer, director, or
Employee of it or any of its Subsidiaries other than pursuant to the terms of
agreements in effect prior to December 31, 2002 or in the ordinary course of
business consistent with past practice, or (6) the entering into of any
agreement or commitment to do any of the foregoing.
(j) Litigation. Except as Previously Disclosed or set forth in its
Annual Report on Form 10-K for the fiscal year ended December 31, 2002 or
Regulatory Filings filed with the SEC since December 31, 2002 and prior to the
date hereof, there is no suit, action, audit, claim, investigation or proceeding
pending or, to its knowledge, threatened in writing against or affecting it or
any of its Subsidiaries (and it is not aware of any basis for any such suit,
action, audit, claim, investigation, or proceeding) that, individually or in the
aggregate, is reasonably likely to (1) be material to it and its Subsidiaries,
taken as a whole, or (2) prevent or delay it in any material respect from
performing its obligations under, or consummating the transactions contemplated
by, this Agreement. To its knowledge, as of the date hereof, none of its
officers or directors or the officers and directors of any of its Subsidiaries
is a defendant in any claim, action, suit or proceeding commenced by any of its
stockholders or any stockholder (or comparable equity owner) of its Subsidiaries
with respect to the performance of his or her duties in such capacity, nor is it
aware of any demand by any of its stockholders that it commence any claim,
action, suit or proceeding against any of its officers or directors.
(k) Owned Real Property. Section 5.03(k) of its Disclosure Letter sets
forth a complete and accurate list of the real property owned by it or any of
its Subsidiaries (the "Owned Real Property"). It or one of its Subsidiaries has
good fee simple title (or other similar title in jurisdictions outside the
United States) to the Owned Real Property free and clear of any Liens or
defects.
(l) Leases.
(1) Section 5.03(l) of its Disclosure Letter sets forth a list
of all material leases, subleases and occupancy agreements, together
with all amendments and supplements thereto, with respect to all real
properties in which it or any of its Subsidiaries has a leasehold
interest, whether as lessor or lessee (each, a "Lease" and
collectively, the "Leases"; the property covered by Leases under which
it or such Subsidiary is a lessee is referred to herein as the "Leased
Real Property").
(2) Each Lease is in full force and effect. Neither it nor any
of its Subsidiaries is in default under any Lease and, to its
knowledge, no other Person party to a Lease is in default.
(m) Intellectual Property. Section 5.03(m) of the Disclosure Letter
sets forth an accurate and complete list of: (i) all registered Marks, and all
pending applications for registration of any Marks anywhere in the world, owned
by it or its Subsidiaries; (ii) all Patents and application for Patents,
anywhere in the world, owned by it or its Subsidiaries; (iii) all registered
Copyrights and pending applications for registration of any Copyrights anywhere
in the world owned by it or its Subsidiaries; and (iv) all Software owned by it
or its Subsidiaries that is material to the operation of its business as
presently conducted, but excluding off-the-shelf
33
and in-licensed Software (collectively, "Owned Intellectual Property"). Except
as set forth in Section 5.03(m) of the Disclosure Letter, it and its
Subsidiaries own all right, title, and interest in the Owned Intellectual
Property. It or its Subsidiaries own, or are licensed or otherwise possess legal
enforceable rights to use the Intellectual Property Rights that are used in its
businesses, and the businesses of its Subsidiaries, as currently conducted. To
its knowledge, all material patents, trademarks, trade names, service marks and
copyrights held by it or its Subsidiaries are valid and subsisting. To its
knowledge, it and its Subsidiaries are not infringing any intellectual property
rights of any other Person. To its knowledge, no claim is pending or, to its
knowledge, threatened with respect to the ownership, validity, license or use
of, or any infringement resulting from, the Intellectual Property Rights. To its
knowledge, the Intellectual Property Rights are not being infringed or
misappropriated by any other Person. There are no restrictions on the direct or
indirect transfer of the Intellectual Property Rights that would be triggered by
the transactions contemplated hereby. To its knowledge, it and its Subsidiaries
have taken reasonable precautions in accordance with standard industry practice
to protect the secrecy, confidentiality and value of all material Trade Secrets
of it or its Subsidiaries, including requiring their employees and officers to
execute and deliver confidentiality, assignment of rights and non-disclosure
agreements. To its knowledge, no employee of it or its Subsidiaries is in
violation of any material term of any confidentiality or nondisclosure
agreement.
(n) Insurance. All material insurance policies carried by or covering
it and its Subsidiaries with respect to their businesses, assets and properties
are in full force and effect, and, to its knowledge, no notice of cancellation
has been given with respect to any such policy. Neither it nor any of its
Subsidiaries has assigned, pledged or transferred any rights under any such
insurance policies. There are no claims by it or any Subsidiary under any such
policy or instrument as to which any insurance company is denying liability or
defending under a reservation of rights clause (other than a customary
reservation of rights clause). All necessary notifications of claims have been
made by it or its Subsidiaries to insurance carriers.
(o) Regulatory Matters.
(1) To its knowledge, all manufacturing, processing,
distribution, labeling, storage, testing, specifications, sale or
marketing of products performed by or on behalf of it and its
Subsidiaries are in compliance with all applicable laws, rules,
regulations, guidances or orders administered or issued by the Food and
Drug Administration, the Drug Enforcement Agency and any other
Governmental Authority.
(2) To its knowledge, all pre-clinical and clinical
investigations conducted or sponsored by it or any of its Subsidiaries
are being conducted in compliance with all recommendations of the Food
and Drug Administration and all applicable laws, rules, regulations and
guidances, including Good Laboratory Practices, investigational new
drug requirements, Good Clinical Practice requirements (including
informed consent and institutional review boards designed to ensure the
protection of the rights and welfare of human subjects), and federal
and state laws, rules, regulations and guidances restricting the use
and disclosure of individually identifiable health information. To its
knowledge, neither it nor any of its Subsidiaries has received any
information which could reasonably be expected to lead to the denial of
any application for approval currently pending before the Food and Drug
Administration.
34
(3) Neither it nor any of its Subsidiaries has received any
oral or written communication (including any warning letter, untitled
letter, Form 483s or similar notices), or is otherwise aware of any
action or proceeding pending or, to its knowledge, threatened
(including any prosecution, injunction, seizure, civil fine, suspension
or recall), in each case alleging that it or any of its Subsidiaries is
not currently in compliance with any and all applicable laws,
regulations or orders implemented by the Food and Drug Administration,
the Drug Enforcement Agency, or any other Governmental Authority
responsible for regulating the pharmaceutical industry. To its
knowledge, none of its Employees is or has been the subject of any
similar pending or threatened action or proceeding.
(4) Neither it nor any of its Subsidiaries has received any
correspondence from the Food and Drug Administration regarding, or is
aware of, any pending or threatened action or proceeding against it,
any of its Subsidiaries or any of its Employees regarding any debarment
action or investigation undertaken pursuant to the Generic Drug
Enforcement Act of 1992, 21 U.S.C. Section 335(a), (b) and (c), or any
other similar regulation of the Food and Drug Administration.
(5) To its knowledge, no data generated by it or any of its
Subsidiaries that has been provided to its clients is the subject of
any regulatory or other action, either pending or threatened, by the
Food and Drug Administration or other Governmental Authority relating
to the truthfulness or scientific adequacy of such data.
(6) To its knowledge, neither it nor any of its Subsidiaries
is the subject, officially or otherwise, of any pending or threatened
investigation by the Food and Drug Administration pursuant to its
Fraud, Untrue, Material Facts, Bribery, and Illegal Gratuities Final
Policy or by the Department of Health and Human Services Office of
Inspector General ("OIG") or United States Department of Justice
("DOJ") pursuant to the Federal Anti-Kickback Statute (42 U.S.C.
Section 1320a-7(b)) and the Civil False Claims Act (31 U.S.C. Section
3729 et seq.) and the regulations promulgated pursuant to such
statutes. To its knowledge, neither it nor any of its Subsidiaries nor
any of its Employees has knowingly committed any act, made any
statement, or failed to make any statement, that would reasonably be
expected to provide a basis for the Food and Drug Administration to
invoke its Fraud, Untrue, Material Facts, Bribery, and Illegal
Gratuities Final Policy or that would reasonably be expected to provide
a basis for liability under the Federal Anti-Kickback Statute or the
Civil False Claims Act and any regulations promulgated thereunder.
(p) Environmental.
(1) It and its Subsidiaries are in compliance with all, and
have no Liability under any, applicable Environmental Laws. There is no
claim with respect to Environmental Laws pending or, to its knowledge,
threatened against it or any of its Subsidiaries and, to its knowledge,
there are no facts or circumstances that could give rise to such a
claim that could reasonably be expected to have, individually or in the
aggregate, a Material Adverse Effect. Neither it nor any of its
Subsidiaries has either assumed or undertaken, or agreed to assume or
undertake, responsibility for any Liability
35
or obligation of any other Person, arising under or relating to
Environmental Laws, including any obligation for investigation or
corrective or remedial action, other than an assumption by operation of
law as the result of the merger of a Person with and into it or any of
its Subsidiaries.
(2) "Liability" means all indebtedness, obligations and other
liabilities and contingencies of a Person, whether absolute, accrued,
contingent, fixed or otherwise, or whether due or to become due.
(3) "Environmental Law" means any federal, state, local,
provincial, foreign, civil and criminal Law, statute, ordinances,
common law, rules, regulations, policies and guidance documents with
the effect of law, now in effect and as amended, and any judicial or
administrative interpretation thereof, including any judicial or
administrative order, consent decree or judgment, relating to
pollution, health, worker health and safety or protection of the
environment, including those relating to the use, handling,
transportation, treatment, storage, disposal, release, exposure or
discharge of Hazardous Substances.
(4) "Hazardous Substances" means (i) petroleum and petroleum
products, by-products or breakdown products, radioactive materials,
asbestos-containing materials and polychlorinated biphenyls, and (ii)
any other chemicals, materials or substances regulated as toxic or
hazardous or as a pollutant, contaminant or waste under any applicable
Environmental Law.
(q) Compliance with Laws. Each of it and its Subsidiaries:
(1) has all permits, licenses, authorizations, orders and
approvals of, and has made all filings, applications and registrations
with (the "Permits"), all Governmental Authorities (including all
authorizations under the Federal Food, Drug and Cosmetic Act of 1938,
as amended and the regulations of the United States Food and Drug
Administration promulgated thereunder) that are required for it to own
or lease and operate its properties or other assets and to conduct its
business in the manner described in the Regulatory Filings prior to the
date hereof and as it is presently conducted, and all such Permits are
valid and in full force and effect and, to its knowledge, no event has
occurred which permits, or upon the giving of notice or passage of time
or both, would permit revocation, non-renewal, modification,
suspension, limitation or termination of any Permit;
(2) conducts its business in compliance with all applicable
Laws, and is not in conflict with, or in default or violation of, any
Law applicable to it or by which any of its property or assets is
bound, or any Permits; and
(3) has received, since December 31, 2000, no written
notification from any Governmental Authority (A) asserting that it or
any of its Subsidiaries is not in compliance with any Law which such
Governmental Authority enforces or (B) threatening to revoke any
Permit.
36
(r) Material Contracts; Defaults.
(1) As of the date hereof, except as filed as exhibits to its
Regulatory Filings prior to the date of this Agreement, neither it nor
any of its Subsidiaries is a party to, and none of their respective
assets, businesses or operations is bound by, any contract, agreement,
commitment, arrangement, lease or other instrument (whether written or
oral) that (a) is a "material contract" (as such term is defined in
Item 601(a)(10) of Regulation S-K promulgated under the Securities
Act), (b) relates to any indebtedness in excess of $10,000,000, (c)
provides for aggregate payments from it or any of its Subsidiaries in
excess of $10,000,000, has an unexpired term exceeding six months and
cannot be terminated without penalty upon not more than 30 days' prior
written notice, or (d) materially limits its freedom or the freedom of
any of its Subsidiaries to compete in any line of business or with any
Person or in any geographical area or which would so materially limit
its freedom or the freedom of any of its Subsidiaries so to compete
after the Effective Time (collectively, its "Material Contracts"). Each
of its Material Contracts is valid and binding on it or its Subsidiary
party thereto and, to its knowledge, each other Person thereto, and is
in full force and effect and enforceable against it or such Subsidiary,
as the case may be, in accordance with its terms, (except as
enforcement may be limited by (i) applicable bankruptcy, insolvency,
reorganization, moratorium, fraudulent transfer and similar laws of
general applicability relating to or affecting creditors' rights or by
general equity principles and (ii) to the extent applicable, securities
laws limitations on the enforceability of provisions regarding
indemnification in connection with the sale or issuance of securities).
No customer party to a Material Contract has given notice of
termination or notice of election to self manufacture products
currently manufactured by CIMA or aaiPharma, as applicable.
(2) Neither it nor any of its Subsidiaries is in violation,
breach or default under any of its Material Contracts, and there has
not occurred any event that, with the lapse of time or the giving of
notice or both, would constitute such a violation, breach or default.
(s) Customers. Since December 31, 2002, neither it nor any of its
Subsidiaries has received written notice that any material customer intends to
cancel, terminate or otherwise modify any relationship with it or any of its
Subsidiaries.
(t) Employees; Labor Relations. Neither it nor any of its Subsidiaries
is a party to, or bound by, any collective bargaining agreement or other
contract or understanding with a labor union or labor organization. There is no
(i) unfair labor practice, labor dispute (other than routine individual
grievances) or labor arbitration proceeding pending or, to its knowledge,
threatened against it or any of its Subsidiaries, (ii) to its knowledge,
activity or proceeding by a labor union or representative thereof to organize
any of its employees or any employees of any of its Subsidiaries, or (iii)
lockouts, strikes, slowdowns, work stoppages or to its knowledge threats thereof
by or with respect to such employees.
37
(u) Employee Benefit Plans.
(1) All Benefits Arrangements covering its current employees
or former employees and those of its Subsidiaries (collectively,
"Employees", and each individually, an "Employee") and its current or
former directors and those of its Subsidiaries, including: (i)
"employee benefit plans" within the meaning of Section 3(3) of ERISA;
and (ii) deferred compensation, stock option, stock purchase, stock
appreciation rights, stock based, incentive and bonus plans
(collectively, "Benefit Plans" and each individually, a "Benefit
Plan"), are Previously Disclosed. True and complete copies of all
Benefit Plan Documents, including any trust instruments and insurance
contracts forming a part of any Benefit Plan Documents, and all
amendments thereto, have been made available to the other party.
(2) All of its Benefit Plans, other than "multiemployer plans"
within the meaning of Section 3(37) of ERISA, to the extent subject to
ERISA, are in substantial compliance with ERISA. Each Benefit Plan
which is an "employee pension benefit plan" within the meaning of
Section 3(2) of ERISA ("Pension Plan"), and which is intended to be
qualified under Section 401(a) of the Code, is so qualified, and has
received a favorable determination letter from the Internal Revenue
Service, or the remedial amendment period under applicable Internal
Revenue Service guidance in which to apply for such letter and make any
amendments that are necessary to obtain a favorable determination as to
the current qualified status of such Pension Plan has not yet expired,
and it is not aware of any circumstances reasonably likely to result in
revocation of any such favorable determination letter. Each Benefit
Plan which is intended to be part of or funded through a voluntary
employees' beneficiary association within the meaning of Section
501(c)(9) of the Code has (i) received an opinion letter from the
Internal Revenue Service recognizing its exempt status under Section
501(c)(9) of the Code and (ii) filed a timely notice with the Internal
Revenue Service pursuant to Section 505(c) of the Code, and it is not
aware of circumstances likely to result in the loss of the exempt
status of such Benefit Plan under Section 501(c)(9) of the Code. There
is no material pending or, to the knowledge of CIMA or aaiPharma, as
the case may be, threatened litigation relating to its Benefit
Arrangements (other than a claim for benefits in the ordinary course).
Neither it, nor to the knowledge of CIMA or aaiPharma, as the case may
be, any plan fiduciary of any Benefit Arrangement, has engaged in any
transaction in violation of Sections 404 or 406 of ERISA or any
"prohibited transaction," as defined in Section 4975(c)(1) of the Code,
for which no exemption exists under Section 408 of ERISA or Section
4975(c)(2) or (d) of the Code, or has otherwise violated the provisions
of Part 4 of Title I, Subtitle B of ERISA. It has not knowingly
participated in a violation of Part 4 of Title I, Subtitle B of ERISA
by any plan fiduciary of any Benefit Arrangement and has not been
assessed any civil penalty under Section 502(l) of ERISA.
(3) No liability under Subtitle C or D of Title IV of ERISA
has been or is reasonably expected to be incurred by it, any of its
Subsidiaries, or any of their respective ERISA Affiliates with respect
to any ongoing, frozen or terminated "single-employer plan," within the
meaning of Section 4001(a)(15) of ERISA, currently or formerly
maintained by any of them. None of it, any of its Subsidiaries, or any
of their respective ERISA Affiliates has contributed to a
"multiemployer plan," within the meaning of
38
Section 3(37) of ERISA, at any time on or after September 26, 1980. No
notice of a "reportable event," within the meaning of Section 4043 of
ERISA, for which the 30-day reporting requirement has not been waived,
has been required to be filed for any Benefit Arrangement which is an
"employee pension benefit plan" within the meaning of Section 3(2) of
ERISA within the 12-month period ending on the date hereof.
(4) All contributions required to be made under the terms of
any of its Benefit Arrangements have been timely made or have been
reflected on its consolidated financial statements included in its
Regulatory Filings. No Benefit Arrangement has an "accumulated funding
deficiency" (whether or not waived) within the meaning of Section 412
of the Code or Section 302 of ERISA and neither it, nor any of its
Subsidiaries or their respective ERISA Affiliates has an outstanding
funding waiver. Neither it nor any of its Subsidiaries or their
respective ERISA Affiliates has provided, or is required to provide,
security to any of its Benefit Arrangements pursuant to Section
401(a)(29) of the Code.
(5) There has been no amendment to, announcement by it or any
of its Subsidiaries relating to, or change in Employee participation or
coverage under, any Benefit Plan that would increase materially the
expense of maintaining such Benefit Plan above the level of the expense
incurred therefor for the most recently completed fiscal year. Neither
its execution of this Agreement, the performance of its obligations
hereunder, the consummation of the transactions contemplated by this
Agreement, the termination of the employment of any of its employees
within a specified time of the Effective Time nor stockholder approval
of the transactions covered by this Agreement, will (x) limit its
right, in its sole discretion, to administer or amend in any respect or
terminate any of its Benefit Plans or any related trust, (y) entitle
any of its Employees to severance pay or any increase in severance pay,
or (z), except as expressly contemplated hereby, accelerate the time of
payment or vesting or trigger any payment or funding (through a grantor
trust or otherwise) of compensation or benefits under, increase the
amount payable or trigger any other material obligation pursuant to,
any of its Benefit Plans. Without limiting the foregoing, as a result
of the consummation of the transactions contemplated by this Agreement
(including, as a result of the termination of the employment of any of
its employees within a specified time of the Effective Time) neither it
nor any of its Subsidiaries will be obligated to make a payment to an
individual that would be a "parachute payment" to a "disqualified
individual" as those terms are defined in Section 280G of the Code,
without regard to whether such payment is reasonable compensation for
personal services performed or to be performed in the future.
(v) Related Party Transactions. Except as disclosed in Regulatory
Filings filed prior to the date of this Agreement, since December 31, 2002,
neither it nor any of its Subsidiaries has entered into any relationship or
transaction of the sort that would be required to be disclosed by it pursuant to
Item 404 of Regulation S-K promulgated under the Securities Act.
(w) Taxes. (1) All Tax Returns that are required to be filed (taking
into account any extensions of time within which to file) by or with respect to
it and its Subsidiaries have been duly and timely filed, and all such Tax
Returns are complete and accurate in all material respects,
39
(2) all Taxes shown to be due on the Tax Returns referred to in clause (1) or
that are otherwise due and payable have been paid in full, except for Taxes
which are being contested in good faith and for which adequate reserves have
been established on the balance sheets contained in the financial statements
contained in the Regulatory Filings filed prior to the date hereof, (3) all
Taxes that it or any of its Subsidiaries is obligated to withhold from amounts
owing to any Employee, creditor or third party have been paid over to the proper
Governmental Authority in a timely manner, to the extent due and payable, and
(4) no extensions or waivers of statutes of limitation have been given by or
requested with respect to any of its U.S. federal income taxes or those of its
Subsidiaries. Its unpaid Taxes and those of its Subsidiaries did not, as of the
dates of the most recent financial statements contained in the Regulatory
Filings filed before the date hereof, exceed the reserve for Liabilities for
Taxes (excluding any reserve for deferred Taxes established to reflect timing
differences between book and Tax income) set forth on the face of the balance
sheets (rather than in any notes thereto) contained in such financial
statements. Since December 31, 2002, neither it nor any of its Subsidiaries has
(x) incurred any Liability for Taxes outside the ordinary course of business or
otherwise inconsistent with past custom and practice, (y) changed its Tax
elections or the Tax elections of any of its Subsidiaries or any accounting
method used by it or any of its Subsidiaries for Tax purposes, where such Tax
election or change in accounting method has had, or is reasonably likely to
have, individually or in the aggregate, a Material Adverse Effect, or (z)
settled or compromised any material liability for income Taxes of it and its
Subsidiaries taken as a whole. It has delivered or made available to the other
party complete and accurate copies of its federal, state and local Tax Returns
and those of its Subsidiaries and each of their predecessors for the years ended
December 31, 1999, 2000 and 2001, and complete and accurate copies of all
examination reports and statements of deficiencies assessed against or agreed to
by any of it and its Subsidiaries or any predecessors since December 31, 1999.
There are no pending or, to its knowledge, threatened audits, assessments or
other actions for or relating to any Liability in respect of Taxes (including
any deficiencies for Taxes) of any of it or its Subsidiaries, and there are no
matters under discussion with Governmental Authorities, or known to it, with
respect to Taxes that are likely to result in an additional Liability for Taxes
with respect to any of it and its Subsidiaries. As of the date hereof, neither
it nor any of its Subsidiaries has taken any action or has any reason to believe
that any conditions exist that could reasonably be expected to prevent or impede
either the aaiPharma Merger or the CIMA Merger from qualifying as a
reorganization within the meaning of Section 368(a) of the Code or the Mergers,
taken together, from qualifying as an exchange described in Section 351 of the
Code. No Liens for Taxes exist with respect to any of its assets or properties
or those of its Subsidiaries, except for statutory Liens for Taxes not yet
delinquent or that are being contested in good faith and reserved for in
accordance with GAAP. Neither it nor any of its Subsidiaries has been a party to
any distribution as either a "distributing corporation" or a "controlled
corporation" in which the parties to such distribution treated the distribution
as one to which Section 355 of the Code applied (i) in the two (2) years prior
to the date of this Agreement, or (ii) which could otherwise constitute part of
a "plan" or "series of related transactions" (within the meaning of Section
355(e) of the Code) that includes the CIMA Merger or aaiPharma Merger, as
applicable. Except for the affiliated group of which it is the common parent,
each of it and its Subsidiaries is not and has never been a member of an
affiliated group of corporations within the meaning of Section 1504 of the Code
or any group that has filed a combined, consolidated or unitary Tax Return.
Neither it nor any of its Subsidiaries has liability for the Taxes of any Person
(including an individual, corporation, general or limited partnership,
40
limited liability company, joint venture, estate, trust, association,
organization, labor union or other entity or Governmental Authority) other than
it and its Subsidiaries (i) under Treasury Regulations Section 1.1502-6 (or any
similar provision of state, local or foreign Law), (ii) as a transferee or
successor, (iii) by contract, or (iv) otherwise. Neither it nor any of its
Subsidiaries has entered into any transaction identified as a "listed
transaction" for purposes of Treasury Regulations Section 1.6011-4(b)(2) or
301.6111-2(b)(2). If either it or any of its Subsidiaries has entered into any
transaction such that, if the treatment claimed by it or its Subsidiaries were
to be disallowed, the transaction would constitute a substantial understatement
of federal income tax within the meaning of Section 6662 of the Code, then it
believes that it has either (x) substantial authority for the tax treatment of
such transaction or (y) disclosed on its Tax Return the relevant facts affecting
the tax treatment of such transaction.
(x) Books and Records; Internal Controls. It maintains a system of
internal controls for financial reporting sufficient to provide reasonable
assurance (i) that records are maintained in reasonable detail that accurately
and fairly reflect the transactions and dispositions of its assets; (ii) that
transactions are recorded as necessary to permit preparation of financial
statements in accordance with GAAP, and that its receipts and expenditures are
being made only in accordance with authorizations of its management and
directors; and (iii) regarding prevention or timely detection of any
unauthorized acquisition, use or disposition of its assets that could have a
material effect on its financial statements.
(y) Marketable Investments. Section 5.03(y) of its Disclosure Letter
lists by amount and type each available-for-sale security owned by it or any of
its Subsidiaries as of a recent date. There are no restrictions of any kind
which prevent or restrict the sale of such available-for-sale securities.
(z) Takeover Laws and Provisions. It has taken all action required to
be taken by it in order to exempt this Agreement, the aaiPharma Voting
Agreements (in the case of aaiPharma), the CIMA Voting Agreements (in the case
of CIMA) and the transactions contemplated hereby and thereby from, and this
Agreement, the aaiPharma Voting Agreements (in the case of aaiPharma), the CIMA
Voting Agreements (in the case of CIMA) and the transactions contemplated hereby
and thereby are exempt from, the requirements of any "moratorium", "control
share", "fair price", "affiliate transaction", "business combination" or other
antitakeover laws and regulations of any state (collectively, "Takeover Laws"),
other than Section 203 of the DGCL. The action of its Board of Directors in
approving this Agreement (and the transactions provided for herein) is
sufficient to render inapplicable to this Agreement (and the transactions
provided for herein) the restrictions on "business combinations" (as defined in
Section 203 of the DGCL) as set forth in Section 203 of the DGCL. It has taken
all action required to be taken by it in order to make this Agreement, the
aaiPharma Voting Agreements (in the case of aaiPharma), the CIMA Voting
Agreements (in the case of CIMA) and the transactions contemplated hereby and
thereby comply with, and this Agreement, the aaiPharma Voting Agreements (in the
case of aaiPharma), the CIMA Voting Agreements (in the case of CIMA) and the
transactions contemplated hereby and thereby do comply with, the requirements of
any Articles, Sections or provisions of its Constituent Documents concerning
"business combination", "fair price", "voting requirement", "constituency
requirement" or other related provisions (collectively, "Takeover Provisions").
41
(aa) Financial Advisors, Etc. None of it, its Subsidiaries or any of
their officers, directors or Employees has employed any broker or finder or
incurred any liability for any brokerage fees, commissions or finder's fees in
connection with the transactions contemplated herein, except that, in connection
with this Agreement, aaiPharma represents to CIMA that aaiPharma has retained
Banc of America Securities, LLC as its financial advisor with respect to the
transactions contemplated by this Agreement and has also retained Xxxxxx Xxxxxx
Partners LLC solely for the purpose of providing certain advisory services in
connection with the transactions contemplated by this Agreement, and CIMA
represents to aaiPharma that CIMA has retained Deutsche Bank Securities Inc. as
its financial advisor with respect to the transactions contemplated by this
Agreement, the arrangements with which have been disclosed to the other party
prior to the date hereof. As of the date hereof:
(1) CIMA represents to aaiPharma that the CIMA Board has
received a written opinion of Deutsche Bank Securities Inc. to the
effect that, as of the date of such opinion, the CIMA Exchange Ratio is
fair from a financial point of view to the holders of CIMA Common
Stock.
(2) aaiPharma represents to CIMA that the aaiPharma Board has
received a written opinion of Banc of America Securities LLC to the
effect that, as of the date of such opinion, the aaiPharma Exchange
Ratio is fair from a financial point of view to the holders of
aaiPharma Common Stock.
(bb) Recommendations of Boards of Directors.
(1) CIMA represents to aaiPharma that the CIMA Board, by
resolution adopted by vote of at least a majority of the CIMA Board
(which resolutions have not been rescinded or amended) at a meeting
duly called and held, at which a quorum was present and acting
throughout, has (i) determined that this Agreement and the transactions
contemplated hereby are advisable, fair to, and in the best interests
of, CIMA and the stockholders of CIMA, (ii) approved this Agreement and
transactions contemplated hereby, and any other matters required to be
approved or adopted in order to effect the Mergers and other
transactions contemplated by this Agreement, which approval has not
been rescinded or modified, (iii) resolved to recommend approval and
adoption of this Agreement by its stockholders, and (iv) directed that
this Agreement be submitted to its stockholders for consideration in
accordance with the terms of this Agreement.
(2) aaiPharma represents to CIMA that the aaiPharma Board, by
resolution adopted by vote of at least a majority of the aaiPharma
Board (which resolutions have not been rescinded or amended) at a
meeting duly called and held, at which a quorum was present and acting
throughout, has (i) determined that this Agreement and the transactions
contemplated hereby are advisable, fair to, and in the best interests
of, aaiPharma and the stockholders of aaiPharma, (ii) approved this
Agreement and transactions contemplated hereby, and any other matters
required to be approved or adopted in order to effect the Mergers and
other transactions contemplated by this Agreement, which approval has
not been rescinded or modified, (iii) resolved to recommend approval
and adoption of this Agreement by its stockholders, and (iv)
42
directed that this Agreement be submitted to its stockholders for
consideration in accordance with the terms of this Agreement.
(cc) CIMA has amended the CIMA Rights Agreement to ensure that (i) none
of a "Distribution Date" or a "Shares Acquisition Date" (in each case as defined
in the CIMA Rights Agreement) will occur, and none of aaiPharma or any of its
stockholders or any of their "Affiliates" or "Associates" as of the date hereof
(including Holding Company) will be deemed to be an "Acquiring Person" (in each
case as defined in the CIMA Rights Agreement) by reason of the execution and
delivery of this Agreement or the consummation of the transactions contemplated
hereby; and (ii) the Rights will expire immediately prior to the Effective Time.
No "Distribution Date" or "Shares Acquisition Date" has occurred.
5.04 Representations and Warranties With Respect to Holding Company and
Subsidiaries. Except as Previously Disclosed, aaiPharma and Holding Company
hereby represent and warrant to CIMA, as follows:
(a) Capital Stock of Holding Company. The authorized capital stock of
Holding Company consists of 1,000 shares of HoldCo Common Stock, of which 100
shares are outstanding, all of which outstanding shares are held of record and
beneficially by aaiPharma.
(b) Capital Stock of Merger Subsidiaries. The authorized capital stock
of S MergerCo consists of 1,000 shares of S MergerCo Common Stock, of which 100
shares are outstanding, all of which outstanding shares are held of record and
beneficially by Holding Company. The authorized capital stock of C MergerCo
consists of 1,000 shares of C MergerCo Common Stock, of which 100 shares are
outstanding, all of which outstanding shares are held of record and beneficially
by Holding Company.
(c) No Business Activities. None of Holding Company, C MergerCo or S
MergerCo has conducted any activities or incurred any Liabilities other than in
connection with its organization and maintenance of good standing, the
negotiation and execution of this Agreement and the consummation of the
transactions contemplated hereby. Holding Company has no Subsidiaries other than
C MergerCo and S MergerCo, and neither C MergerCo nor S MergerCo has any
Subsidiaries.
ARTICLE VI
COVENANTS
6.01 Reasonable Best Efforts.
(a) Subject to the terms and conditions of this Agreement, aaiPharma
and CIMA will use all reasonable best efforts to take, or cause to be taken, in
good faith, all actions, and to do, or cause to be done, all things necessary,
proper or desirable, or advisable under applicable laws, so as to permit
consummation of the Mergers as promptly as practicable and otherwise to enable
consummation of the transactions contemplated hereby, and each will cooperate
fully with, and furnish information to, the other party to that end.
43
(b) Neither CIMA nor aaiPharma shall, nor shall they permit any of
their respective Subsidiaries (including Holding Company, C MergerCo and S
MergerCo) to, take or cause to be taken any action that would disqualify either
Merger as a reorganization within the meaning of Section 368(a) of the Code.
CIMA and aaiPharma shall use their reasonable best efforts, and shall cause
their respective Subsidiaries to use their reasonable best efforts, to take or
cause to be taken each action that is required to cause each Merger to qualify
as a reorganization within the meaning of Section 368(a) of the Code and the
Mergers, taken together, to qualify as an exchange described in Section 351 of
the Code.
(c) CIMA and Holding Company shall report the CIMA Merger, and
aaiPharma and Holding Company shall report the aaiPharma Merger, as
reorganizations within the meaning of Section 368 of the Code, unless otherwise
required pursuant to a "determination" within the meaning of Section 1313(a) of
the Code.
(d) If requested by aaiPharma, at any time Holding Company shall
execute a guarantee, supplemental indenture and such other documents as shall be
required to guarantee the payment of aaiPharma's 11% Senior Subordinated Notes
due 2010.
(e) As soon as reasonably practicable following the execution of this
Agreement, aaiPharma, as the holder of all of the outstanding shares of HoldCo
Common Stock, will approve and adopt this Agreement and will cause Holding
Company, as the sole stockholder of each of C MergerCo and S MergerCo, to
approve the Mergers and adopt this Agreement.
(f) At the Effective Time, Holding Company shall assume the obligations
of aaiPharma under the Registration Rights Agreement, dated as of November 17,
1995, among aaiPharma and the stockholders of aaiPharma party thereto.
6.02 Registration Statement; Joint Proxy Statement; Stockholder
Approvals.
(a) As promptly as reasonably practicable following the date hereof,
CIMA and aaiPharma shall prepare and file with the SEC mutually acceptable joint
proxy materials relating to the CIMA Meeting and the aaiPharma Meeting (such
proxy statement, and any amendments or supplements thereto, the "Joint Proxy
Statement"), and aaiPharma shall cause Holding Company to prepare and file a
registration statement on Form S-4 with respect to the issuance of HoldCo Common
Stock pursuant to the Mergers (the "Registration Statement"; the prospectus
contained in the Registration Statement together with the Proxy Statement, the
"Joint Proxy Statement/Prospectus"). Each of CIMA and aaiPharma agrees to
cooperate, and to cause its Subsidiaries to cooperate, with the other party, its
counsel and its accountants, in the preparation of the Registration Statement
and the Joint Proxy Statement. The Joint Proxy Statement shall be included in
and shall constitute a part of the Registration Statement as Holding Company's
prospectus. The Registration Statement and the Joint Proxy Statement shall
comply as to form in all material respects with the applicable provisions of the
Securities Act and the Exchange Act and the rules and regulations thereunder.
Each of CIMA and aaiPharma shall use reasonable best efforts to have the
Registration Statement declared effective by the SEC as promptly as practicable
after the date hereof and to keep the Registration Statement effective as long
as is necessary to consummate the Mergers and the other transactions
contemplated thereby. CIMA and aaiPharma shall, as promptly as practicable after
receipt thereof, provide the other party
44
copies of any written comments and advise the other party of any oral comments
with respect to the Joint Proxy Statement received from the SEC. CIMA and
aaiPharma shall provide the other party with a reasonable opportunity to review
and comment on any amendment or supplement to the Registration Statement and the
Joint Proxy Statement prior to filing such with the SEC, and will promptly
provide the other party with a copy of all such filings made with the SEC. CIMA
and aaiPharma shall mail the Joint Proxy Statement/Prospectus to their
respective stockholders, in each case, as soon as reasonably practicable after
the Registration Statement is declared effective under the Securities Act and
the Joint Proxy Statement shall have been cleared by the SEC; provided, however,
that CIMA and aaiPharma shall consult and cooperate with each other in
determining the appropriate time for mailing the Joint Proxy
Statement/Prospectus in light of the date set for the CIMA Meeting and the
aaiPharma Meeting. aaiPharma shall cause Holding Company to take any action
(other than qualifying to do business in any jurisdiction in which it is not now
so qualified or to file a general consent to service of process) required to be
taken under any applicable federal or state securities laws in connection with
the issuance of HoldCo Common Stock pursuant to the transactions contemplated by
this Agreement. Each of CIMA, aaiPharma and Holding Company shall furnish all
information concerning it and the holders of its capital stock as any party
hereto may reasonably request in connection with such actions and the
preparation of the Registration Statement and the Proxy Statement.
(b) Each of aaiPharma and CIMA will advise the other party, promptly
after it receives notice thereof, of the time when the Registration Statement
has become effective, the issuance of any stop order, the suspension of the
qualification of the HoldCo Common Stock issuable in connection with the Mergers
for offering or sale in any jurisdiction, or any request by the SEC for
amendment of the Joint Proxy Statement or the Registration Statement.
(c) aaiPharma, CIMA and Holding Company each agrees, as to itself and
its Subsidiaries, that none of the information supplied or to be supplied by it
for inclusion or incorporation by reference in (i) the Registration Statement
will, at the time the Registration Statement and each amendment or supplement
thereto, if any, becomes effective under the Securities Act, contain any untrue
statement of a material fact or omit to state any material fact required to be
stated therein or necessary to make the statements therein not misleading and
(ii) the Joint Proxy Statement and any amendment or supplement thereto will, at
the date of mailing to stockholders and at the time of the aaiPharma Meeting or
the CIMA Meeting, as the case may be, contain any untrue statement of a material
fact or omit to state any material fact required to be stated therein or
necessary to make the statements therein, in the light of the circumstances
under which such statement was made, not misleading. If, at any time prior to
the Effective Time, any information relating to CIMA, aaiPharma, Holding Company
or any of their Subsidiaries, or any of their respective Affiliates, officers or
directors, should be discovered by CIMA, aaiPharma or Holding Company that
should be set forth in an amendment or supplement to any of the Registration
Statement or the Joint Proxy Statement so that any of such documents would not
include any misstatement of a material fact or omit to state any material fact
necessary to make the statements therein, in light of the circumstances under
which they were made, not misleading, the party which discovers such information
shall promptly notify the other party hereto and, to the extent required by Law,
an appropriate amendment or supplement describing such information shall be
promptly filed with the SEC and disseminated to the stockholders of CIMA and
aaiPharma.
45
(d) Notwithstanding any other provision in this Agreement to the
contrary, no amendment or supplement (including by incorporation by reference)
to the Joint Proxy Statement or the Registration Statement shall be made without
the approval of both aaiPharma and CIMA, which approval shall not be
unreasonably withheld or delayed; provided that with respect to documents filed
by a party which are incorporated by reference in the Registration Statement or
Joint Proxy Statement, this right of approval shall apply only with respect to
information relating to the other party or its business, financial condition or
results of operations; provided, further, that CIMA, in connection with a Change
in the CIMA Recommendation (as defined in Section 6.02(f)), and aaiPharma, in
connection with a Change in the aaiPharma Recommendation (as defined in Section
6.02(e)), may amend or supplement the Joint Proxy Statement or Registration
Statement (including by incorporation by reference) pursuant to a Qualifying
Amendment (as defined below) to effect such a Change, and in such event, the
right of approval shall apply only with respect to information relating to the
other party or its business, financial condition or results of operations, and
shall be subject to the right of each party to have its Board of Directors'
deliberations and conclusions accurately described. A "Qualifying Amendment"
means an amendment or supplement to the Joint Proxy Statement or Registration
Statement (including by incorporation by reference) to the extent it contains
(i) a Change in the CIMA Recommendation or a Change in the aaiPharma
Recommendation (as the case may be), (ii) a statement of the reasons of the CIMA
Board or the aaiPharma Board (as the case may be) for making such Change in the
CIMA Recommendation or Change in the aaiPharma Recommendation (as the case may
be) and (iii) additional information reasonably related to the foregoing.
(e) Prior to the termination of this Agreement, aaiPharma shall duly
take all lawful action to call, give notice of, convene and hold a meeting of
its stockholders (the "aaiPharma Meeting") as soon as reasonably practicable
following the date the Registration Statement becomes effective and the Joint
Proxy Statement is cleared by the SEC and after coordination with CIMA for the
purpose of obtaining the aaiPharma Stockholder Approval; provided that subject
to applicable Law, so long as the Registration Statement becomes effective and
the Joint Proxy Statement is cleared by the SEC, in each case not later than
thirty Business Days prior to the Termination Date, the aaiPharma Meeting shall
be held not later than five Business Days prior to the Termination Date;
provided, further, that aaiPharma shall not be required to hold the aaiPharma
Meeting prior to the date of the CIMA Meeting. In connection with the aaiPharma
Meeting and the transactions contemplated hereby, aaiPharma will (i) subject to
applicable Law and this Section 6.02(e), use its reasonable best efforts
(including postponing or adjourning the aaiPharma Meeting to obtain a quorum or
to solicit additional proxies) to obtain the necessary approvals by its
stockholders of this Agreement and (ii) otherwise comply with all legal
requirements applicable to the aaiPharma Meeting. The Board of Directors of
aaiPharma shall recommend adoption of this Agreement by the stockholders of
aaiPharma as set forth in Section 5.03(bb)(2) (the "aaiPharma Recommendation"),
and shall not withdraw, modify or qualify (or propose to withdraw, modify or
qualify) (a "Change") in any manner adverse to CIMA such recommendation or take
any action or make any statement in connection with the aaiPharma Meeting
inconsistent with such recommendation (collectively, a "Change in the aaiPharma
Recommendation"); provided that the foregoing shall not prohibit accurate
disclosure (and such disclosure shall not be deemed to be a Change in the
aaiPharma Recommendation) of factual information regarding the business,
financial condition or results of operations of CIMA or aaiPharma or the fact
that an Acquisition Proposal has been made, the identity of the party
46
making such proposal or the material terms of such proposal (provided that the
aaiPharma Board does not withdraw, modify or qualify (or propose to withdraw,
modify or qualify) in any manner adverse to CIMA the aaiPharma Recommendation)
in the Registration Statement or the Joint Proxy Statement or otherwise, to the
extent such information, facts, identity or terms is required to be disclosed
under applicable Law; and, provided, further, that the aaiPharma Board may make
a Change in the aaiPharma Recommendation pursuant to Section 6.03(e) hereof.
Notwithstanding any Change in the aaiPharma Recommendation, this Agreement shall
be submitted to the stockholders of aaiPharma at the aaiPharma Meeting for the
purpose of adopting this Agreement and approving the aaiPharma Merger; provided
that this Agreement shall not be required to be submitted to the stockholders of
aaiPharma at the aaiPharma Meeting if this Agreement has been terminated
pursuant to Section 8.01 hereof. For purposes of this Agreement, a Change in the
aaiPharma Recommendation shall be deemed to include a recommendation by the
aaiPharma Board of a third party Acquisition Proposal with respect to aaiPharma.
(f) Prior to the termination of this Agreement, CIMA shall duly take
all lawful action to call, give notice of, convene and hold a meeting of its
stockholders (the "CIMA Meeting") as soon as reasonably practicable following
the date the Registration Statement becomes effective and the Joint Proxy
Statement is cleared by the SEC and after coordination with aaiPharma for the
purpose of obtaining the CIMA Stockholder Approval; provided that, subject to
applicable Law, so long as the Registration Statement becomes effective and the
Joint Proxy Statement is cleared by the SEC not later than thirty Business Days
prior to the Termination Date, the CIMA Meeting shall be held not later than
five Business Days prior to the Termination Date; provided, further, that CIMA
shall not be required to hold the CIMA Meeting prior to the date of the
aaiPharma Meeting. In connection with the CIMA Meeting and the transactions
contemplated hereby, CIMA will (i) subject to applicable Law and this Section
6.02(f), use its reasonable best efforts (including postponing or adjourning the
CIMA Meeting to obtain a quorum or to solicit additional proxies) to obtain the
necessary approvals by its stockholders of this Agreement and (ii) otherwise
comply with all legal requirements applicable to the CIMA Meeting. The CIMA
Board shall recommend adoption of this Agreement by the stockholders of CIMA as
set forth in Section 5.03(bb)(1) (the "CIMA Recommendation"), and shall not
Change in any manner adverse to aaiPharma such recommendation or take any action
or make any statement in connection with the CIMA Meeting inconsistent with such
recommendation (collectively, a "Change in the CIMA Recommendation"); provided
that the foregoing shall not prohibit accurate disclosure (and such disclosure
shall not be deemed to be a Change in the CIMA Recommendation) of factual
information regarding the business, financial condition or results of operations
of CIMA or aaiPharma or the fact that an Acquisition Proposal has been made, the
identity of the party making such proposal or the material terms of such
proposal (provided that the CIMA Board does not withdraw, modify or qualify (or
propose to withdraw, modify or qualify) in any manner adverse to aaiPharma the
CIMA Recommendation) in the Registration Statement or the Joint Proxy Statement
or otherwise, to the extent such information, facts, identity or terms is
required to be disclosed under applicable Law; and, provided further, that the
CIMA Board may make a Change in the CIMA Recommendation pursuant to Section
6.03(e) hereof. Notwithstanding any Change in the CIMA Recommendation, this
Agreement shall be submitted to the stockholders of CIMA at the CIMA Meeting for
the purpose of adopting this Agreement and approving the CIMA Merger; provided
that this Agreement shall not be required to be submitted to the stockholders of
CIMA at the CIMA Meeting if this Agreement has been
47
terminated pursuant to Section 8.01 hereof. For purposes of this Agreement, a
Change in the CIMA Recommendation shall be deemed to include a recommendation by
the CIMA Board of a third party Acquisition Proposal with respect to CIMA.
(g) Nothing in this Section 6.02 shall permit either party to terminate
this Agreement (except as specifically provided in Article VIII).
6.03 Acquisition Proposals.
(a) After the date hereof and prior to the Effective Time or earlier
termination of this Agreement, each of CIMA and aaiPharma agrees that neither it
nor any of its Subsidiaries nor any of the officers, directors or employees of
it or its Subsidiaries shall, and that it shall use its reasonable best efforts
to cause its and its Subsidiaries' other Representatives not to, directly or
indirectly, (i) initiate, solicit, encourage, knowingly facilitate or induce any
inquiry with respect to, or the making, submission or announcement of, any
Acquisition Proposal, (ii) participate in any discussions or negotiations
regarding, or furnish to any Person any nonpublic information with respect to,
or take any other action to facilitate any inquiries or the making of any
proposal that constitutes or may reasonably be expected to lead to, any
Acquisition Proposal (except to notify such Person as to the existence of these
provisions or to the extent specifically permitted pursuant to this Section
6.03), (iii) accept, approve, endorse or recommend any Acquisition Proposal
(except to the extent specifically permitted pursuant to this Section 6.03), or
(iv) enter into any letter of intent or similar document or any agreement,
commitment or understanding contemplating or otherwise relating to any
Acquisition Proposal or a transaction contemplated thereby (except for
confidentiality agreements specifically permitted pursuant to Section
6.03(c)(3)). Each of aaiPharma, CIMA and their officers, directors and employees
will immediately cease and cause to be terminated, and shall use its reasonable
best efforts to cause its and its Subsidiaries' other Representatives to
immediately cease and terminate, any activities, discussions or negotiations
conducted before the date of this Agreement with any Persons other than CIMA or
aaiPharma, as the case may be, with respect to any Acquisition Proposal, and
will use its reasonable best efforts to enforce any confidentiality or similar
agreement relating to any such Acquisition Proposal.
(b) aaiPharma and CIMA will as promptly as practicable (and in no event
later than within one Business Day after receipt thereof) notify the other party
in writing following receipt of any Acquisition Proposal or any request for
nonpublic information or inquiry which it reasonably believes could lead to an
Acquisition Proposal. Such notice shall set forth in reasonable detail the
substance and material terms of such Acquisition Proposal, request or inquiry
(including the identity of the Person making such Acquisition Proposal, request
or inquiry). aaiPharma and CIMA will keep the other party apprised of any
related developments, discussions and negotiations (including any material
changes or modifications to the terms and conditions of the Acquisition
Proposal, request or inquiry) on a current basis, and provide to the other
party, as soon as reasonably practicable, copies of all written materials
provided or made available in connection with such Acquisition Proposal, request
or inquiry (including the form of any merger agreement or acquisition agreement,
as the case may be, in connection with any such Acquisition Proposal). aaiPharma
and CIMA shall provide the other party with forty-eight (48) hours' prior notice
(or such lesser prior notice as is provided to the members of its Board of
48
Directors) of any meeting of its Board of Directors at which such Board of
Directors is reasonably expected to consider any Acquisition Proposal.
(c) Notwithstanding anything in this Agreement to the contrary, each of
CIMA and aaiPharma shall be permitted to engage in discussions or negotiations
with, and provide nonpublic information to, any Person that has made unsolicited
bona fide written Acquisition Proposal with respect to it, if and only to the
extent that:
(1) the CIMA Stockholder Approval, in the case of CIMA, or the
aaiPharma Stockholder Approval, in the case of aaiPharma, respectively,
shall not have been obtained;
(2) (x) its Board of Directors has concluded in good faith,
after consultation with a nationally recognized financial advisor and
its outside legal counsel, such Acquisition Proposal constitutes a
Superior Proposal (and continues to constitute a Superior Proposal
after taking into account any amendment or modification to this
Agreement proposed by the other party hereto during any three Business
Day period referenced below in Section 6.03(d)), or (y) its Board of
Directors concludes in good faith, after consultation with a nationally
recognized financial advisor and its outside legal counsel, that there
is a reasonable likelihood that such Acquisition Proposal would
reasonably be expected to result in a Superior Proposal;
(3) prior to providing any nonpublic information to any
Person, it shall have entered into a confidentiality agreement with
such third party on terms no less favorable to it than the
Confidentiality Agreement; and
(4) prior to providing any nonpublic information to any Person
or entering into discussions or negotiations with any Person, it has
notified the other party to this Agreement promptly of such Acquisition
Proposal (a "Superior Proposal Notice") and has otherwise complied with
its obligations under Section 6.03(b).
(d) For a period of not less than three Business Days after CIMA's or
aaiPharma's delivery of any Superior Proposal Notice to the other party, it
shall, if requested by the other party, negotiate in good faith with the other
party to revise this Agreement so that the Acquisition Proposal that constituted
a Superior Proposal no longer constitutes a Superior Proposal (a "Former
Superior Proposal"). The terms and conditions of this Section 6.03 shall again
apply to any inquiry or proposal made by any Person who withdraws a Superior
Proposal or who made a Former Superior Proposal (after withdrawal or after such
time as such proposal is a Former Superior Proposal).
(e) Notwithstanding anything in this Agreement to the contrary, each of
CIMA and aaiPharma shall be permitted to effect a Change in CIMA Recommendation
or a Change in aaiPharma Recommendation, as the case may be, if and only to the
extent that:
(1) the CIMA Stockholder Approval, in the case of CIMA, or the
aaiPharma Stockholder Approval, in the case of aaiPharma, respectively,
shall not have been obtained;
49
(2) it shall have (x) provided written notice to the other
party stating that it intends to change its recommendation and the
manner in which it intends to do so, and (y) complied with its
obligations under Sections 6.03(b) and (d); and
(3) its Board of Directors has concluded in good faith, after
receipt of advice of its outside legal counsel, that the failure of the
Board of Directors to effect a Change in CIMA Recommendation or a
Change in aaiPharma Recommendation, as applicable, would result in a
breach of its fiduciary obligations to its stockholders under
applicable Law.
(f) Nothing contained in this Agreement shall prohibit CIMA or
aaiPharma or their Board of Directors from taking and disclosing to their
stockholders a position contemplated by Rules 14d-9 and 14e-2(a) promulgated
under the Exchange Act, provided that the content of any such disclosure
thereunder shall be governed by the terms of this Agreement. Without limiting
the foregoing proviso, neither CIMA nor aaiPharma shall effect a Change in CIMA
Recommendation or a Change in aaiPharma Recommendation, respectively, unless
specifically permitted pursuant to the terms of Section 6.03(e).
(g) Neither CIMA nor aaiPharma shall submit to the vote of its
stockholders any Acquisition Proposal, or propose to do so, prior to termination
of this Agreement.
(h) Each of CIMA and aaiPharma agrees that it will use reasonable best
efforts to promptly inform its Representatives of the obligations undertaken in
this Section 6.03.
6.04 Holding Company Board and Officers.
(a) At the Effective Time, the Holding Company Board shall consist of
eight directors, four of whom shall be current members of the aaiPharma Board
designated prior to the Effective Time by aaiPharma and four of whom shall be
current members of the CIMA Board designated prior to the Effective Time by CIMA
(collectively, such designees and any replacements therefor are referred to as
the "Board Designees"). Prior to the Effective Time, CIMA shall designate two of
its Board Designees who are Independent Directors and aaiPharma shall designate
three of its Board Designees who are Independent Directors to serve on a
selection committee (the "Selection Committee") of the Holding Company Board to
select and elect certain additional members of the Holding Company Board as set
forth in Section 6.04(b). Each of CIMA and aaiPharma shall notify the other
party of its Board Designees and those Board Designees designated to serve on
the Selection Committee no later than two Business Days prior to the Effective
Time. aaiPharma and Holding Company agree to take all action necessary to elect
the Board Designees to serve as the Holding Company Board immediately prior to
the Effective Time. aaiPharma and Holding Company agree to take all action
necessary to cause the Holding Company Board to establish the Selection
Committee as a committee of the Holding Company Board, immediately prior to the
Effective Time, empowered to take all actions described in Section 6.04(b)
below. In the event that, prior to the Effective Time, any of the Board
Designees or of the designated members of the Selection Committee becomes unable
or unwilling to serve as a member of the Holding Company Board or Selection
Committee, respectively, the party designating such Board Designee or member of
the Selection Committee, as the case may be, may designate a replacement Board
Designee or member of the Selection
50
Committee as applicable; provided that any replacement member of the Selection
Committee must be an Independent Director.
(b) Within 20 Business Days after the Effective Time, the Selection
Committee shall select up to three individuals (the "Additional Directors") to
serve as members of the Holding Company Board, each of whom shall have agreed so
to serve. Each of the Additional Directors shall be Independent Directors unless
the Selection Committee unanimously agrees otherwise. The Selection Committee
may meet in person or by teleconference and at such time or times as it shall
determine for such purpose. In selecting Additional Directors, the Selection
Committee shall consider all current members of the CIMA Board and the aaiPharma
Board who are not then members of the Holding Company Board, as well as any
other individuals suggested to the Selection Committee by any member of the
Holding Company Board. Concurrently with selecting the Additional Directors, the
Selection Committee shall take all action necessary to set the number of members
of the Holding Company Board at the appropriate number (nine (9), ten (10) or
eleven (11)) and then appoint the Additional Directors to the resulting
vacancies. Action by the Selection Committee pursuant to this Section 6.04(b)
shall require the affirmative vote of a majority of the members of the Selection
Committee.
(c) Immediately prior to the Effective Time, aaiPharma and Holding
Company shall take all action necessary (i) to remove or cause the resignation
of all members of the Holding Company Board who are not Board Designees, (ii) to
remove all of the officers of Holding Company and (iii) to appoint as officers
of Holding Company the individuals identified in Exhibit 6.04(c) to the offices
set forth opposite their names in Exhibit 6.04(c), as such Exhibit may be
amended prior to the Effective Time in accordance with Section 9.02.
6.05 Press Releases; Public Announcements. aaiPharma and CIMA shall
consult with each other before issuing, and provide each other the opportunity
to review and make reasonable comment upon, any press release, written employee
communication or other written stockholder communication with respect to the
Mergers or this Agreement and shall not issue, or allow any of their respective
Subsidiaries to issue, any such communication or make any such public statement
without the prior consent of the other party, which will not be unreasonably
withheld or delayed; provided that a party may, without the prior consent of the
other party (but after prior consultation, to the extent practicable in the
circumstances), issue such communication or make a Regulatory Filing or other
public statement that may be required by applicable Law or securities exchange
rules on which the HoldCo Common Stock, the CIMA Common Stock or aaiPharma
Common Stock is listed, as applicable; provided, further, that a party may make
any public statement in response to specific questions by the press, analysts,
investors or those attending industry conferences or financial analyst
conference calls, so long as any such statements are not inconsistent with
previous press releases, public disclosures or public statements made jointly by
CIMA and aaiPharma and do not reveal any non-public information regarding the
other party. aaiPharma and CIMA shall cooperate to develop all public
communications and make appropriate members of management available at
presentations related to the transactions contemplated by this Agreement as
reasonably requested by the other party.
51
6.06 Access; Information.
(a) Each of aaiPharma and CIMA agrees that upon reasonable notice and
subject to applicable Laws relating to the exchange of information, it shall
(and shall cause its Subsidiaries to) afford the other party, and the other
party's Representatives, such access during normal business hours, upon
reasonable notice, throughout the period before the Effective Time to the books,
records (including Tax Returns and work papers of independent accountants),
properties, personnel and to such other information as any party may reasonably
request and, during such period, it will furnish promptly to such other party
all information concerning the business, properties and personnel of it as the
other may reasonably request; provided that such investigation shall not
unreasonably disrupt the furnishing party's operations. Neither party nor any of
its Subsidiaries shall be required to afford access or disclose information that
would jeopardize attorney-client privilege or contravene any binding agreement
with any third party. The parties shall make appropriate substitute arrangements
in circumstances where the previous sentence applies.
(b) Each party agrees that it shall hold as confidential any
information that is nonpublic and confidential to the extent required by, and in
accordance with, the Confidentiality Agreement, dated as of May 27, 2003,
between aaiPharma and CIMA (the "Confidentiality Agreement"). Notwithstanding
anything to the contrary set forth in this Agreement or in any other written or
oral understanding or agreement to which the parties hereto are parties or by
which they are bound, including the Confidentiality Agreement, the parties
hereto acknowledge and agree that any obligations of confidentiality contained
herein and therein shall not apply to the Tax treatment and Tax structure of the
Mergers upon the earlier to occur of (i) the date of the public announcement of
discussions relating to the Mergers, (ii) the date of the public announcement of
the Mergers, or (iii) the date of the execution of the Agreement, all within the
meaning of Treasury Regulations Section 1.6011-4; provided, however, that each
party recognizes that the privilege each has to maintain, in its sole
discretion, the confidentiality of a communication relating to the Mergers,
including a confidential communication with its attorney or a confidential
communication with a federally authorized tax practitioner under Section 7525 of
the Code, is not intended to be affected by the foregoing.
(c) No investigation by either party of the business and affairs of the
other party, pursuant to this Section 6.06 or otherwise, shall affect or be
deemed to modify or waive any representation, warranty, covenant or agreement in
this Agreement, or the conditions to either party's obligation to consummate the
transactions contemplated by this Agreement.
6.07 Takeover Laws and Rights Plans.
(a) No party shall take any action that would cause the transactions
contemplated by this Agreement to be subject to requirements imposed by any
Takeover Law, and each of them shall take all necessary steps within its control
to exempt (or ensure the continued exemption of) those transactions from, or if
necessary challenge the validity or applicability of, any applicable Takeover
Law, as now or hereafter in effect. No party shall take any action that would
cause the transactions contemplated by this Agreement not to comply with any
Takeover Provisions, and each of them shall take all necessary steps within its
control to make those transactions comply with (or continue to comply with) the
Takeover Provisions.
52
(b) The CIMA Board shall not, without the prior written consent of
aaiPharma, (i) amend the CIMA Rights Agreement or (ii) take any action to, or
make any determination under, the CIMA Rights Agreement, including a redemption
of the CIMA Rights, except upon the termination of this Agreement pursuant to
Section 8.01(i).
(c) aaiPharma shall not adopt any stockholder rights plan or similar
agreement prior to the Effective Time.
6.08 Nasdaq Listing. CIMA, aaiPharma and Holding Company shall use all
reasonable best efforts to cause the shares of HoldCo Common Stock to be issued
pursuant to the Mergers and to be issued upon the exercise of CIMA Stock Options
or aaiPharma Stock Options following the Effective Time to be approved for
listing on Nasdaq, subject to official notice of issuance, as promptly as
practicable, and in any event before the Effective Time.
6.09 Regulatory and Third Party Approvals.
(a) Subject to the terms and conditions herein provided, CIMA and
aaiPharma shall:
(1) as promptly as reasonably practicable make their
respective filings under the HSR Act with respect to the Mergers, and
thereafter promptly make any other required submissions under the HSR
Act;
(2) use their reasonable best efforts to cooperate with one
another in (A) determining which filings are required to be made prior
to the Effective Time with, and which consents, approvals, permits or
authorizations are required to be obtained prior to the Effective Time
from Governmental Authorities in connection with the execution and
delivery of this Agreement and the consummation of the Mergers and the
transactions contemplated hereby (the "Requisite Regulatory Approvals")
and (B) timely making all such filings in respect of those Requisite
Regulatory Approvals and timely seeking all such Requisite Regulatory
Approvals;
(3) use their reasonable best efforts to prepare and file, as
applicable, as soon as is reasonably practical, all documentation to
effect and obtain all Requisite Regulatory Approvals;
(4) promptly notify each other as soon as is reasonably
practicable of any material communication concerning this Agreement or
the transactions contemplated hereby (including the Mergers) to that
party or its Subsidiaries from any Governmental Authority and permit
the other party to review in advance any proposed communications
concerning this Agreement or the transactions contemplated hereby
(including the Mergers) to any Governmental Authority;
(5) to the extent reasonably practicable, not agree to
participate in any meeting or discussion with any Governmental
Authority in respect of any filings, investigation or other inquiry
concerning this Agreement or the transactions contemplated hereby
(including the Mergers) unless it consults with the other party in
advance and, to the extent reasonably practicable and permitted by such
Governmental Authority, gives the other party the opportunity to attend
and participate in the meeting or discussion;
53
(6) furnish the other party with copies of all material
correspondence, filings and communications (and memoranda setting forth
the substance thereof) between them and their Affiliates and their
respective Representatives on the one hand, and any Governmental
Authority or members or their respective staffs on the other hand, with
respect to this Agreement and the Mergers;
(7) furnish the other party with such necessary information
and reasonable assistance as such other party and its Affiliates may
reasonably request in connection with their preparation of necessary
filings, registrations or submissions of information to any
Governmental Authority, including any filings necessary or appropriate
under the provisions of the HSR Act; and
(8) not voluntarily extend any waiting period under the HSR
Act and/or enter into any agreement with a Governmental Authority to
delay or not to consummate the Mergers except with the prior written
consent of the other party, which consent shall not be unreasonably
withheld or delayed (which reasonableness shall be determined in light
of CIMA's and aaiPharma's obligation to consummate the Mergers as
promptly as reasonably practicable following the date of this
Agreement).
CIMA, aaiPharma and their respective Subsidiaries may designate any
competitively sensitive information provided to the other under this
Section 6.09(a) as "outside counsel only." Such information shall be
given only to outside counsel of the recipient. In addition, CIMA,
aaiPharma and their respective Subsidiaries may redact any
competitively sensitive information from such documents shared with the
other party or its counsel that is not pertinent to the subject matter
of a Requisite Regulatory Approval.
(b) Without limiting Section 6.09(a), CIMA and aaiPharma shall:
(1) each use its reasonable best efforts to avoid the entry
of, or to have vacated or terminated, any decree, order or judgment
that would restrain, prevent or delay the Closing, including defending
through litigation on the merits any claim asserted in any court by any
party; and
(2) each use its reasonable best efforts to avoid or eliminate
impediments under any antitrust, competition or trade regulation law
that may be asserted by any Governmental Authority with respect to the
Mergers so as to enable the Closing to occur as soon as reasonably
possible (and in any event prior to the Termination Date), provided
that nothing in this Section 6.09 shall require either CIMA or
aaiPharma to (i) license, sell, divest or dispose of any material
assets or businesses of CIMA or aaiPharma or any of their respective
Subsidiaries or (ii) otherwise take or commit to take any action that
limits in any material respect its freedom of action with respect to,
or its ability to retain, any of the assets or businesses of CIMA or
aaiPharma or any of their respective Subsidiaries.
(c) Each of CIMA and aaiPharma shall give (or shall cause their
respective Subsidiaries to give) any notices to non-governmental third parties,
and use, and cause their respective Subsidiaries to use, reasonable best efforts
to obtain any non-governmental third party
54
consents with respect to it, (i) necessary, proper or advisable to consummate
the transactions contemplated by this Agreement, (ii) required to be disclosed
in Section 5.03(g) of the CIMA Disclosure Letter or the aaiPharma Disclosure
Letter, as applicable, or (iii) required to prevent a CIMA Material Adverse
Effect or a aaiPharma Material Adverse Effect from occurring prior to or after
the Effective Time. In the event that either party shall fail to obtain any
third party consent described in the first sentence of this Section 6.09(c),
such party shall use reasonable best efforts, and shall take any such actions
reasonably requested by the other party hereto, to minimize any adverse effect
upon CIMA and aaiPharma, their respective Subsidiaries, and their respective
businesses resulting, or which could reasonably be expected to result after the
Effective Time, from the failure to obtain such consent; provided that no
obligation to make a material payment or to grant a material right shall be
imposed by this Section 6.09(c).
6.10 Indemnification.
(a) Following the Effective Time, Holding Company will indemnify,
defend and hold harmless, and provide advancement of expenses to, the present
and former directors and officers of CIMA or any of its Subsidiaries and the
present and former directors and officers of aaiPharma or any of its
Subsidiaries (each, an "Indemnified Party"), to the fullest extent permitted by
Law, against all costs or expenses (including reasonable attorneys' fees),
judgments, fines, losses, claims, damages or liabilities (collectively, "Costs")
as incurred, in connection with any claim, action, suit, proceeding or
investigation, whether civil, criminal, administrative or investigative, arising
out of actions or omissions occurring at or before the Effective Time (including
the transactions contemplated by this Agreement).
(b) For a period of six years following the Effective Time, Holding
Company shall, and shall cause CIMA Surviving Corporation and aaiPharma
Surviving Corporation to, cause to be maintained in effect in the Constituent
Documents of each of CIMA Surviving Corporation and aaiPharma Surviving
Corporation, as the case may be, or any successor of either, provisions with
respect to exculpation, indemnification and advancement of expenses that are at
least as favorable to the intended beneficiaries as those presently contained in
the Constituent Documents of CIMA and aaiPharma, as the case may be, to the
extent permitted by Law.
(c) For a period of six years following the Effective Time, Holding
Company shall, or shall cause aaiPharma Surviving Corporation and CIMA Surviving
Corporation, as applicable, to, provide director's and officer's liability
insurance for the benefit of the present and former officers and directors of
CIMA or any of its Subsidiaries or aaiPharma or its Subsidiaries with respect to
claims against such directors and officers arising from facts or events
occurring before the Effective Time (including the transactions contemplated by
this Agreement), which insurance will contain at least the same coverage (and
not less than $15,000,000 of coverage with respect to CIMA) and amounts, and
contain terms and conditions no less advantageous to the Indemnified Party as
that coverage currently provided to such Indemnified Party by CIMA or aaiPharma,
as the case may be; provided, however, that Holding Company, CIMA Surviving
Corporation and aaiPharma Surviving Corporation collectively shall not be
required to pay annual premiums in excess of $4,000,000, in which case Holding
Company shall, or shall cause aaiPharma Surviving Corporation and CIMA Surviving
Corporation, as applicable, to obtain in the aggregate as much comparable
insurance as is reasonably available for such amount to provide, to the extent
practicable, the same amount of coverage with respect to the present and
55
former officers and directors of CIMA and any of its Subsidiaries as coverage
with respect to the present and former officers and directors of aaiPharma and
any of its Subsidiaries; and provided, further, that an Indemnified Party may be
required to make application and provide customary representations and
warranties to Holding Company's insurance carrier for the purpose of obtaining
such insurance.
(d) The rights of each Indemnified Party hereunder shall be in addition
to, and not in limitation of, any other rights such Indemnified Party may have
under the Constituent Documents of CIMA or aaiPharma, any other indemnification
arrangement, the DGCL or otherwise. The provisions of this Section 6.10 shall
survive the consummation of the Mergers.
(e) If Holding Company, CIMA Surviving Corporation, aaiPharma Surviving
Corporation or any of their respective successors or assigns consolidates with
or merges into any other entity and is not the continuing or surviving entity of
such consolidation or merger or transfers all or substantially all of its assets
to any other entity, then and in each case, Holding Company will cause proper
provision to be made so that the successors and assigns of Holding Company, CIMA
Surviving Corporation or aaiPharma Surviving Corporation, as the case may be,
shall assume the obligations set forth in this Section 6.10.
(f) The provisions of this Section 6.10 are expressly intended to be
for the benefit of, and shall be enforceable by, each Indemnified Party and his
or her heirs and Representatives.
6.11 Benefit Plans.
(a) From and after the Effective Time, Holding Company shall, and shall
cause its Subsidiaries (including CIMA Surviving Corporation and aaiPharma
Surviving Corporation), to cause the Benefit Arrangements maintained by each of
them after the Effective Time to recognize, at the least, each Continued
Employee's years of service and employment and level of seniority with any one
of them prior to the Effective Time for purposes of eligibility, vesting,
benefit accrual and benefit determination under such Benefit Arrangements (other
than benefit accruals under any defined benefit pension plan) maintained by any
one of them after the Effective Time to the same extent that such years of
service and employment and level of seniority were recognized by the Continued
Employee's employer's substantially similar Benefit Arrangement immediately
prior to the Effective Time. Moreover, from and after the Effective Time,
Holding Company shall, and shall cause its Subsidiaries (including CIMA
Surviving Corporation and aaiPharma Surviving Corporation) to, cause each
Benefit Plan maintained by any one of them after the Effective Time that a
Continued Employee may be eligible to participate in on or after the Effective
Time to waive any preexisting condition exclusion with respect to participation
and coverage requirements applicable to Continued Employees to the extent that
such exclusion did not apply to the Continued Employee prior to the Effective
Time under any similar Benefit Plan in which the Continued Employee participated
immediately prior to the Effective Time. If after the Effective Time, Holding
Company or any of its Subsidiaries (including CIMA Surviving Corporation and
aaiPharma Surviving Corporation) provides coverage under a group health plan for
Continued Employees (including their eligible dependents) that is different from
the group health plan in which the Continued Employees participated immediately
prior to the Effective Time, then Holding Company shall cause, or shall cause
the plan sponsor to cause, such group health plan to credit such Continued
Employees, for
56
the current year, with any deductibles and co-payments already incurred during
such year under the group health plan in which the Continued Employees
participated immediately prior to the Effective Time.
(b) From and after the Effective Time, Holding Company shall honor,
fulfill and discharge and shall cause CIMA Surviving Corporation and aaiPharma
Surviving Corporation to honor, fulfill and discharge, in accordance with its
terms, each Benefit Arrangement and each employment and termination agreement
(i) between aaiPharma or any of its Subsidiaries and any officer, director or
employee of any of them or (ii) between CIMA and any officer, director or
employee of CIMA, in each case in place immediately prior to the Effective Time,
including (A) all legal and contractual obligations pursuant to outstanding
retirement plans, salary and bonus deferral plans, vested and accrued benefits
and similar employment and benefit arrangements and agreements (specifically
including all of the "change in control" provisions under Benefit Arrangements
of aaiPharma or CIMA) and (B) all vacation, personal and sick days accrued by
Employees as of the Effective Time. At the Effective Time, Holding Company shall
assume the employment agreement between aaiPharma and Xxxxxxxxx X. Xxxxxxxx and
shall honor, fulfill and discharge all responsibilities, and accede to all
rights, of aaiPharma thereunder. From and after the Effective Time, until the
second anniversary of the Effective Time, Holding Company and its Subsidiaries
shall not adopt or modify any Benefit Arrangement that would create or enhance
any disparity in the aggregate compensation and benefits between similarly
situated regular, full time employees of CIMA Surviving Corporation and its
Subsidiaries on the one hand and of aaiPharma Surviving Corporation and its
Subsidiaries on the other hand, other than to reflect local and competitive
employment market conditions. However, nothing contained in any of the foregoing
provisions of this Section 6.11(b) or elsewhere in this Agreement shall (x)
require Holding Company or its Subsidiaries (including CIMA Surviving
Corporation and aaiPharma Surviving Corporation) to continue (A) any particular
compensation or benefits or compensation, benefits or employment agreement for
any particular period of time beyond that to which it is contractually bound or
(B) any Benefit Arrangement for any particular period of time beyond that to
which it is contractually or otherwise legally bound or (y) prevent the
amendment, modification or termination of any such compensation or benefits,
compensation, benefits or employment agreement or Benefit Arrangement except as
may be prohibited by the terms thereof or otherwise by law.
(c) Prior to the Effective Time, CIMA shall take all action necessary
to terminate the CIMA Stock Purchase Plan.
(d) Prior to the Effective Time, CIMA shall take all action necessary
to cause all CIMA Stock Options outstanding immediately prior to the Effective
Time to become fully vested and exercisable immediately prior to the Effective
Time.
6.12 Notification of Certain Matters. aaiPharma and CIMA shall each
give prompt notice to the other party of any fact, event or circumstance known
to it that (i) is reasonably likely, individually or taken together with all
other facts, events and circumstances known to it, to result in any Material
Adverse Effect with respect to it or (ii) would cause or constitute a material
breach of any of its representations, warranties, covenants or agreements
contained herein that reasonably could be expected to give rise, individually or
in the aggregate, to the failure of a condition in Article VII; provided,
however, that the delivery of any notice pursuant
57
to this Section 6.12 shall not cure any breach of any representation or
warranty, the failure to comply with any covenant, the failure to meet any
condition or otherwise limit or affect the remedies available hereunder to the
party receiving such notice.
6.13 Exemption from Liability Under Section 16(b).
(a) Prior to the Effective Time, (i) assuming that aaiPharma delivers
to Holding Company the Section 16 Information in a timely and accurate manner
before the Effective Time, the Holding Company Board, or a committee of
"non-employee directors" thereof (as such term is defined for purposes of Rule
16b-3(d) under the Exchange Act), as the case may be, shall adopt a resolution
consistent with the interpretive guidance of the SEC providing that the receipt
by the aaiPharma Insiders who may be a covered Person of Holding Company for
purposes of Section 16 of the Exchange Act (together with the rules and
regulations promulgated thereunder, "Section 16") of HoldCo Common Stock in
exchange for shares of aaiPharma Common Stock, and of options to purchase shares
of HoldCo Common Stock upon conversion of options to purchase shares of
aaiPharma Common Stock, in each case pursuant to the transactions contemplated
hereby and to the extent such securities are listed in the Section 16
Information, are approved by the Holding Company Board, or by such committee
thereof, as the case may be, and are intended to be exempt from liability
pursuant to Section 16(b) under the Exchange Act, such that any such receipt
will be so exempt and (ii) the aaiPharma Board, or an appropriate committee of
non-employee directors thereof, shall adopt a resolution consistent with the
interpretive guidance of the SEC so that the disposition by any officer or
director of aaiPharma who is a aaiPharma Insider of shares of aaiPharma Common
Stock or aaiPharma Stock Options pursuant to this Agreement and the Mergers
shall be an exempt transaction for purposes of Section 16.
(b) Prior to the Effective Time, (i) assuming that CIMA delivers to
Holding Company the Section 16 Information in a timely and accurate manner
before the Effective Time, the Holding Company Board, or a committee of
"non-employee directors" thereof (as such term is defined for purposes of Rule
16b-3(d) under the Exchange Act), as the case may be, shall adopt a resolution
consistent with the interpretive guidance of the SEC providing that the receipt
by the CIMA Insiders who may be a covered Person of Holding Company for purposes
of Section 16 of HoldCo Common Stock in exchange for shares of CIMA Common
Stock, and of options to purchase shares of HoldCo Common Stock upon conversion
of options to purchase shares of CIMA Common Stock, in each case pursuant to the
transactions contemplated hereby and to the extent such securities are listed in
the Section 16 Information, are approved by the Holding Company Board, or by
such committee thereof, as the case may be, and are intended to be exempt from
liability pursuant to Section 16(b) under the Exchange Act, such that any such
receipt will be so exempt and (ii) the CIMA Board, or an appropriate committee
of non-employee directors thereof, shall adopt a resolution consistent with the
interpretive guidance of the SEC so that the disposition by any officer or
director of CIMA who is a CIMA Insider of shares of CIMA Common Stock or CIMA
Stock Options pursuant to this Agreement and the Mergers shall be an exempt
transaction for purposes of Section 16.
6.14 Affiliate Notices. Each of CIMA and aaiPharma shall, promptly
after the date hereof and prior to the mailing of the Joint Proxy
Statement/Prospectus, deliver to the other party a list setting forth the names
of all Persons such party expects to be, at the time of the CIMA
58
Meeting and the aaiPharma Meeting, as the case may be, "affiliates" of such
party for purposes of Rule 145 under the Securities Act. Each of CIMA and
aaiPharma shall furnish such other information and documents as the other party
may reasonably request for the purpose of reviewing the list. Prior to the
Effective Time, each of aaiPharma and CIMA shall deliver a notice, reasonably
acceptable to the other party, to each such Person identified as an Affiliate in
such list, describing the requirements of Rule 145 applicable to such Affiliates
by reason of the transactions contemplated by this Agreement.
6.15 Rights Plans. Prior to the Effective Time, Holding Company shall
adopt and have in full force and legal effect a stockholder rights agreement
substantially identical in all material respects to the CIMA Rights Plan or in a
form reasonably acceptable to CIMA and aaiPharma, and which exempts aaiPharma as
an "Acquiring Person" prior to the Effective Time, and shall take all such
action as is necessary to declare, immediately prior to the Effective Time, a
dividend of one (1) preferred share purchase right for each outstanding share of
HoldCo Common Stock.
6.16 Control of Other Party's Business. Nothing contained in this
Agreement shall give any party, directly or indirectly, the right to control or
direct the operations of the other party prior to the consummation of the
Mergers. Prior to the consummation of the Mergers, each of aaiPharma and CIMA
shall exercise, consistent with the terms and conditions of this Agreement,
complete control and supervision over its operations.
6.17 Treasury Regulation Statement. On the Closing Date, each of
aaiPharma and CIMA shall deliver to Holding Company a properly executed
statement in accordance with the requirements of Treasury Regulation Section
1.897-2(h) and in a form reasonably acceptable to Holding Company for purposes
of satisfying Holding Company's obligations under Treasury Regulation Section
1.1445-2(c)(3).
ARTICLE VII
CONDITIONS TO THE MERGERS
7.01 Conditions to Each Party's Obligation to Effect the Mergers. The
respective obligations of each of aaiPharma and CIMA to consummate their
respective Mergers are subject to the fulfillment or written waiver by aaiPharma
and CIMA before the Effective Time of each of the following conditions:
(a) Stockholder Approvals. The aaiPharma Stockholder Approval and the
CIMA Stockholder Approval shall have been obtained.
(b) HSR Act. Any waiting period applicable to consummation of the
Mergers under the HSR Act shall have expired or been terminated.
(c) Regulatory Approvals. Other than filings pursuant to the HSR Act,
all consents, approvals and authorizations of any Governmental Authority
required of CIMA, aaiPharma or any of their Subsidiaries to consummate the
Mergers, the failure of which to be obtained or taken, individually or in the
aggregate, would have a Material Adverse Effect on Holding
59
Company (determined, for purposes of this clause, after giving effect to the
Mergers), shall have been obtained.
(d) No Injunction. No Governmental Authority of competent jurisdiction
shall have enacted, issued, promulgated, enforced or entered any statute, rule,
regulation, judgment, decree, injunction or other order (whether temporary,
preliminary or permanent) which is in effect and prohibits consummation of the
Mergers or makes illegal the consummation of the Mergers (each party agreeing to
use its reasonable best efforts, subject to the provisions of Section 6.09,
including appealing to higher courts, to have any judgment, decree, injunction
or order lifted).
(e) Registration Statement. The Registration Statement shall have
become effective under the Securities Act and no stop order suspending the
effectiveness of the Registration Statement shall have been issued and be in
effect and no proceedings for that purpose shall be pending before the SEC.
(f) Listing. The shares of HoldCo Common Stock to be issued pursuant to
the Mergers and to be issued upon the exercise of CIMA Stock Options and
aaiPharma Stock Options following the Effective Time shall have been approved
for listing on Nasdaq, subject to official notice of issuance.
(g) Opinions of Tax Counsel. aaiPharma shall have received a written
opinion of Xxxxxxxx, Xxxxxxxx & Xxxxxx, P.A., and CIMA shall have received a
written opinion of Xxxxxx & Xxxxxxx LLP, each dated the Closing Date and based
on facts, representations and assumptions described in each such opinion, to the
effect that each Merger will be treated as a reorganization within the meaning
of Section 368(a) of the Code and/or that the Mergers, taken together, will be
treated as an exchange described in Section 351 of the Code. In rendering such
opinions, Xxxxxxxx, Xxxxxxxx & Xxxxxx, P.A. and Xxxxxx & Xxxxxxx LLP each will
be entitled to receive and rely upon customary certificates and representations
of officers of aaiPharma and CIMA reasonably satisfactory to such counsel and in
substantially the forms attached hereto as Exhibit 7.01(g).
7.02 Conditions to CIMA's Obligation. CIMA's obligation to consummate
the CIMA Merger is also subject to the fulfillment or written waiver by CIMA
before the Effective Time of each of the following conditions:
(a) aaiPharma's Representations and Warranties. The representations and
warranties of aaiPharma in this Agreement, after giving effect to the standard
set forth in Section 5.02, shall be true and correct as of the date of this
Agreement and (except to the extent such representations and warranties speak as
of an earlier date) as of the Closing Date as though made on and as of the
Closing Date; and CIMA shall have received a certificate, dated the Closing
Date, signed on behalf of aaiPharma by the Chief Executive Officer or Chief
Financial Officer of aaiPharma to that effect.
(b) Performance of aaiPharma's Obligations. aaiPharma shall have
performed or complied with in all material respects all obligations required to
be performed or complied with by it under this Agreement at or before the
Effective Time; and CIMA shall have received a
60
certificate, dated the Closing Date, signed on behalf of aaiPharma by the Chief
Executive Officer or Chief Financial Officer of aaiPharma to that effect.
(c) aaiPharma Material Adverse Effect. Since the date of this
Agreement, there shall not have occurred any Material Adverse Effect on
aaiPharma or any event or development that would, individually or in the
aggregate, reasonably be expected to have a Material Adverse Effect on
aaiPharma.
(d) Election of Holding Company Board. Holding Company shall have taken
all action necessary to, at the Effective Time, appoint to the Holding Company
Board the eight Persons designated pursuant to Section 6.04 (to the extent such
Persons have been designated in accordance with Section 6.04 prior to the
Effective Time).
(e) Appointment of Officers. Holding Company shall have taken all
action necessary to remove all of its officers and appoint as officers of
Holding Company, to the extent such Persons are willing to serve, the Persons
identified in Exhibit 6.04(c) to the offices set forth opposite their names in
Exhibit 6.04(c), as such Exhibit may be amended prior to the Effective Time in
accordance with Section 9.02.
7.03 Conditions to aaiPharma's Obligation. aaiPharma's obligation to
consummate the aaiPharma Merger is also subject to the fulfillment or written
waiver by aaiPharma before the Effective Time of each of the following
conditions:
(a) CIMA's Representations and Warranties. The representations and
warranties of CIMA in this Agreement, after giving effect to the standard set
forth in Section 5.02, shall be true and correct as of the date of this
Agreement and (except to the extent such representations and warranties speak as
of an earlier date) as of the Closing Date as though made on and as of the
Closing Date; and aaiPharma shall have received a certificate, dated the Closing
Date, signed on behalf of CIMA by the Chief Executive Officer or Chief Financial
Officer of CIMA to that effect.
(b) Performance of CIMA's Obligations. CIMA shall have performed or
complied with in all material respects all obligations required to be performed
or complied with by it under this Agreement at or before the Effective Time; and
aaiPharma shall have received a certificate, dated the Closing Date, signed on
behalf of CIMA by the Chief Executive Officer or Chief Financial Officer of CIMA
to that effect.
(c) CIMA Material Adverse Effect. Since the date of this Agreement,
there shall not have occurred any Material Adverse Effect on CIMA or any event
or development that would, individually or in the aggregate, reasonably be
expected to have a Material Adverse Effect on CIMA.
61
ARTICLE VIII
TERMINATION
8.01 Termination. This Agreement may be terminated, and the Mergers may
be abandoned, at any time before the Effective Time, whether before or (except
as restricted below) after approval of the matters presented in connection with
the Mergers by the stockholders of CIMA or aaiPharma:
(a) Mutual Agreement. By aaiPharma or CIMA, with the mutual agreement
of the other party, which agreement shall have been approved by action of their
respective Boards of Directors;
(b) Breach by aaiPharma. By CIMA, if there has occurred and is
continuing a breach by aaiPharma of any representation, warranty, covenant or
agreement contained in this Agreement, after giving effect to the standard set
forth in Section 5.02, that (x) would result in a failure of a condition set
forth in Section 7.02 (a) or (b) and (y) cannot be cured prior to the
Termination Date, provided that CIMA shall have given aaiPharma written notice,
delivered at least 30 days prior to such termination, stating CIMA's intention
to terminate this Agreement pursuant to this Section 8.01(b), absent a cure, and
the basis for such termination;
(c) Breach by CIMA. By aaiPharma, if there has occurred and is
continuing a breach by CIMA of any representation, warranty, covenant or
agreement contained in this Agreement, after giving effect to the standard set
forth in Section 5.02, that (x) would result in a failure of a condition set
forth in Section 7.03 (a) or (b) and (y) cannot be cured prior to the
Termination Date, provided that aaiPharma shall have given CIMA written notice,
delivered at least 30 days prior to such termination, stating aaiPharma's
intention to terminate this Agreement pursuant to this Section 8.01(c), absent a
cure, and the basis for such termination;
(d) Adverse CIMA Action. By aaiPharma, if (i) prior to obtaining the
CIMA Stockholder Approval, the CIMA Board shall have withdrawn or changed or
modified the CIMA Recommendation in a manner adverse to aaiPharma, (ii) prior to
obtaining the CIMA Stockholder Approval, the CIMA Board shall have approved or
recommended to CIMA's stockholders an Acquisition Proposal, (iii) prior to
obtaining the CIMA Stockholder Approval, a tender offer or exchange offer for
shares of CIMA Common Stock is commenced (other than by aaiPharma or any of its
Affiliates) and the CIMA Board fails to recommend that CIMA's stockholders
reject such tender or exchange offer within ten Business Days after receipt of
aaiPharma's request to do so, or (iv) for any reason CIMA fails to call, hold or
convene the CIMA Meeting by the fifth Business Day prior to the Termination Date
(if the CIMA Meeting is required to be held on or prior to such date pursuant to
Section 6.02(f)); provided, however, that aaiPharma's right to terminate this
Agreement under clause (iv) shall not be available if at such time CIMA would be
entitled to terminate this Agreement under Section 8.01(b); provided, further,
that the right to terminate this Agreement under this Section 8.01(d) shall not
be available to aaiPharma after the CIMA Stockholder Approval has been obtained;
(e) Adverse aaiPharma Action. By CIMA, if (i) prior to obtaining the
aaiPharma Stockholder Approval, the aaiPharma Board shall have withdrawn or
changed or modified the
62
aaiPharma Recommendation in a manner adverse to CIMA, (ii) prior to obtaining
the aaiPharma Stockholder Approval, the aaiPharma Board shall have approved or
recommended to aaiPharma's stockholders an Acquisition Proposal, (iii) prior to
obtaining the aaiPharma Stockholder Approval, a tender offer or exchange offer
for shares of aaiPharma Common Stock is commenced (other than by CIMA or any of
its Affiliates) and the aaiPharma Board fails to recommend that aaiPharma's
stockholders reject such tender or exchange offer within ten Business Days after
receipt of CIMA's request to do so, or (iv) for any reason aaiPharma fails to
call, hold or convene the aaiPharma Meeting by the fifth Business Day prior to
the Termination Date (if the aaiPharma Meeting is required to be held on or
prior to such date pursuant to Section 6.02(e)); provided, however, that CIMA's
right to terminate this Agreement under clause (iv) shall not be available if at
such time aaiPharma would be entitled to terminate this Agreement under Section
8.01(c); provided, further, that the right to terminate this Agreement under
this Section 8.01(e) shall not be available to CIMA after the aaiPharma
Stockholder Approval has been obtained;
(f) Delay. By aaiPharma or CIMA, if the Effective Time has not occurred
by the close of business on December 31, 2003; provided that (i) in the event
that the Registration Statement has not become effective or the Joint Proxy
Statement has not been cleared by the SEC on or prior to the date (the "SEC
Deadline Date") that is thirty Business Days prior to December 31, 2003, such
December 31, 2003 date shall be extended by the number of days after the SEC
Deadline Date (not to exceed sixty calendar days) required for both the
Registration Statement to be declared effective and the Joint Proxy Statement to
be cleared by the SEC and (ii) in the event the Closing has not occurred by
December 31, 2003 solely due to the failure to obtain a Requisite Regulatory
Approval (excluding the declaration by the SEC of the effectiveness of the
Registration Statement and the clearance by the SEC of the Joint Proxy
Statement), such December 31, 2003 date shall be extended by sixty days whether
or not extended pursuant to clause (i) of this Section 8.01(f) (the December 31,
2003 date, as extended pursuant to the preceding proviso, the "Termination
Date"); provided, further, that the right to terminate this Agreement under this
Section 8.01(f) shall not be available to any party whose failure to comply with
any provision of this Agreement has been the cause of, or materially contributed
to, the failure of the Effective Time to occur on or before such date;
(g) Stockholders Do Not Approve. By aaiPharma or CIMA, (i) if the CIMA
Stockholder Approval shall not have been obtained at a duly held meeting of the
stockholders of CIMA called for such purpose (including any adjournment or
postponement thereof) or (ii) if the aaiPharma Stockholder Approval shall not
have been obtained at a duly held meeting of the stockholders of aaiPharma
called for such purpose (including any adjournment or postponement thereof);
provided that the right to terminate this Agreement under this Section 8.01(g)
shall not be available to any party whose failure to comply with any provision
of this Agreement has been the cause of, or materially contributed to, the
failure to obtain the CIMA Stockholder Approval or the aaiPharma Stockholder
Approval, as the case may be;
(h) Denial of Regulatory Approval. By aaiPharma or CIMA, if any
Governmental Authority of competent jurisdiction shall have issued an order,
judgment, decision, opinion, decree or ruling or taken any other action (which
the party seeking to terminate shall have used its reasonable best efforts to
resist, resolve, annul, quash, or lift, as applicable) permanently enjoining or
otherwise prohibiting the consummation of the transactions contemplated by this
63
Agreement, and such order, decree, ruling or action shall have become final and
non-appealable; provided that the right to terminate this Agreement under this
Section 8.01(h) shall not be available to any party whose failure to comply with
any provision of this Agreement has been the cause of, or materially contributed
to, such action;
(i) CIMA Superior Proposal. By CIMA, if, prior to receipt of the CIMA
Stockholder Approval, the CIMA Board (i) concludes in good faith, following
receipt of advice of its outside legal counsel, that the failure to accept a
Superior Proposal would result in a breach of its fiduciary duties under
applicable law, and (ii) determines to accept such Superior Proposal, but only
if CIMA fulfills its obligation to pay a termination fee to aaiPharma under
Section 8.02 hereof concurrent with such termination; provided, however, that
CIMA's right to terminate this Agreement under this Section 8.01(i) shall not be
available if CIMA is then in breach of Section 6.03; or
(j) aaiPharma Superior Proposal. By aaiPharma, if, prior to receipt of
the aaiPharma Stockholder Approval, the aaiPharma Board (i) concludes in good
faith, following receipt of advice of its outside legal counsel, that the
failure to accept a Superior Proposal would result in a breach of its fiduciary
duties under applicable law, and (ii) determines to accept such Superior
Proposal, but only if aaiPharma fulfills its obligation to pay a termination fee
to CIMA under Section 8.02 hereof concurrent with such termination; provided,
however, that aaiPharma's right to terminate this Agreement under this Section
8.01(j) shall not be available if aaiPharma is then in breach of Section 6.03.
The party desiring to terminate this Agreement pursuant to Section 8.01
(other than pursuant to Section 8.01(a)) shall give written notice of such
termination to the other parties.
8.02 Effect of Termination and Abandonment.
(a) Limitation of Liability. In the event of any termination of this
Agreement as provided in Section 8.01, this Agreement shall forthwith become
wholly void and of no further force and effect (except with respect to Section
5.03(aa), Section 6.06(b), this Section 8.02 and Article IX, which shall remain
in full force and effect) and there shall be no liability on the part of
aaiPharma, CIMA, Holding Company, C MergerCo or S MergerCo, except with respect
to Section 5.03(aa), Section 6.06(b), this Section 8.02 and Article IX and with
respect to any Liabilities or damages incurred or suffered by a party as a
result of the willful breach by the other party of any of its representations,
warranties, covenants or other agreements set forth in this Agreement (after
giving effect to the standard in Section 5.02).
(b) CIMA Expenses. CIMA and aaiPharma agree that if this Agreement is
terminated pursuant to Section 8.01(b), then aaiPharma shall pay CIMA an amount
equal to the sum of CIMA's Expenses up to an amount equal to $5,500,000.
(c) aaiPharma Expenses. CIMA and aaiPharma agree that if this Agreement
is terminated pursuant to Section 8.01(c), then CIMA shall pay to aaiPharma an
amount equal to the sum of aaiPharma's Expenses up to an amount equal to
$5,500,000.
(d) Payment of Expenses. Payment of Expenses pursuant to Section
8.02(b) or 8.02(c) shall be made not later than two Business Days after delivery
to the other party of notice
64
of demand for payment and a documented itemization setting forth in reasonable
detail all Expenses of the party entitled to receive payment (which itemization
may be supplemented and updated from time to time by such party until the
ninetieth (90th) day after such party delivers such notice of demand for
payment).
(e) aaiPharma Termination Fee. aaiPharma agrees to pay to CIMA (without
duplication) the fees set forth below under the following circumstances:
(1) If (A) this Agreement is terminated pursuant to Section
8.01(g)(ii) or 8.01(e)(iii), and (B) after the date hereof, but prior
to the time of the aaiPharma Meeting, an Acquisition Proposal relating
to aaiPharma had been publicly proposed or publicly announced, and (C)
on or prior to the twelve-month anniversary of the termination of this
Agreement, aaiPharma consummates, or enters into an agreement providing
for, a Competing Transaction, aaiPharma shall pay CIMA a fee of
$11,500,000 at the earlier of the time aaiPharma consummates, or enters
into the agreement providing for a Competing Transaction.
(2) If CIMA terminates this Agreement pursuant to Section
8.01(e)(i), 8.01(e)(ii) or 8.01(e)(iv), aaiPharma shall pay CIMA a fee
of $11,500,000 within two Business Days following termination.
(3) aaiPharma shall pay to CIMA a fee of $11,500,000 prior to
or concurrently with any termination of this Agreement by aaiPharma
pursuant to Section 8.01(j).
In no event shall fees payable by aaiPharma pursuant to Section 8.02(b)
and this Section 8.02(e) exceed $11,500,000.
(f) CIMA Termination Fee. CIMA agrees to pay to aaiPharma (without
duplication) the fees set forth below under the following circumstances:
(1) If (A) this Agreement is terminated pursuant to Section
8.01(g)(i) or 8.01(d)(iii) and (B) after the date hereof, but prior to
the time of the CIMA Meeting, an Acquisition Proposal relating to CIMA
had been publicly proposed or publicly announced, and (C) on or prior
to the twelve-month anniversary of the termination of this Agreement,
CIMA consummates, or enters into an agreement providing for, a
Competing Transaction, CIMA shall pay aaiPharma a fee of $11,500,000 at
the earlier of the time CIMA consummates, or enters into the agreement
providing for a Competing Transaction.
(2) If aaiPharma terminates this Agreement pursuant to Section
8.01(d)(i), 8.01(d)(ii) or 8.01(d)(iv), CIMA shall pay aaiPharma a fee
of $11,500,000 within two Business Days following termination.
(3) CIMA shall pay to aaiPharma a fee of $11,500,000 prior to
or concurrently with any termination of this Agreement by CIMA pursuant
to Section 8.01(i).
65
In no event shall fees payable by CIMA pursuant to Section 8.02(c) and
this Section 8.02(f) exceed $11,500,000.
(g) All payments to be made by a party under this Section 8.02 shall be
made by wire transfer of immediately available funds to an account designated by
the other party.
(h) The parties each agree that the agreements contained in Section
8.02 are integral parts of the transaction contemplated by this Agreement and
that, without these agreements, neither CIMA nor aaiPharma would enter into this
Agreement. Accordingly, if a party fails to promptly pay the other party an
amount due under this Section 8.02, such failing party shall pay the costs and
expenses of such other party (including reasonable legal fees and expenses) in
connection with any action, including the filing of any lawsuit or legal action,
taken to collect payment, together with interest on the amount of the payment at
the prime rate of Citibank, N.A. in effect on the date such payment was required
to be made.
ARTICLE IX
MISCELLANEOUS
9.01 Survival. The representations, warranties, agreements and
covenants contained in this Agreement will not survive the Effective Time (other
than Section 2.04, Article III, Sections 6.04, 6.06(b), 6.10, 6.11 and this
Article IX).
9.02 Waiver; Amendment. At any time before the Effective Time, whether
before or after the CIMA Stockholder Approval or the aaiPharma Stockholder
Approval is obtained, any provision of this Agreement may be (a) waived by the
party benefited by the provision, but only in writing, or (b) amended or
modified at any time, but only by a written agreement executed in the same
manner as this Agreement; provided, however, that after either the CIMA
Stockholder Approval or the aaiPharma Stockholder Approval is obtained, there
shall not be made any amendment or waiver that by law or the listing
requirements of Nasdaq requires further approval by such stockholders of
aaiPharma or CIMA without such further approval first being obtained. At any
time prior to the Effective Time, the parties, by action taken or authorized by
their respective boards of directors, may, to the extent legally allowed, (i)
extend the time for the performance of any of the obligations or other acts of
the other parties, (ii) waive any inaccuracies in the representations and
warranties contained herein or in any document delivered pursuant hereto and
(iii) waive compliance with any of the agreements or conditions contained
herein. Any agreement on the part of a party hereto to any such extension or
waiver shall be valid only if set forth in a written instrument signed on behalf
of such party. The failure of any party to this Agreement to assert any of its
rights under this Agreement or otherwise shall not constitute a waiver of those
rights.
9.03 Counterparts. This Agreement may be executed in one or more
counterparts, each of which will be deemed to constitute an original.
9.04 Governing Law. This Agreement is governed by, and will be
interpreted in accordance with, the laws of the State of
Delaware applicable to
contracts made and to be
66
performed entirely within that State, without regard to the conflicts of laws
principles of any State.
9.05 Expenses. Subject to Section 8.02, in the event that the Mergers
are not consummated pursuant to this Agreement, each party will bear all
expenses incurred by it in connection with this Agreement and the transactions
contemplated hereby, except that aaiPharma and CIMA will each bear and pay
one-half of the following expenses: (i) the costs (excluding the fees and
disbursements of Representatives) incurred in connection with the preparation
(including copying and printing and distributing) of the Registration Statement,
the Joint Proxy Statement and applications to Governmental Authorities for the
approval of the Mergers and (ii) all listing, filing or registration fees,
including fees paid for filing the Registration Statement with the SEC, filing
fees for the HSR Act notices and any other fees paid for filings with
Governmental Authorities. In the event that the Mergers are consummated pursuant
to this Agreement, CIMA will bear all expenses of each party in connection with
this Agreement and the transactions contemplated thereby.
9.06 Notices. All notices, requests and other communications given or
made under this Agreement must be in writing and will be deemed given when
personally delivered, facsimile transmitted (with confirmation), five Business
Days after mailing by registered or certified mail (return receipt requested),
or one Business Day after overnight mailing by reputable overnight courier, to
the Persons and addresses set forth below or such other place as such party may
specify by notice.
If to aaiPharma, Holding Company, C MergerCo or S MergerCo, to:
aaiPharma Inc.
0000 Xxxxxxxxxx Xxxx Xxxxx
Xxxxxxxxxx, Xxxxx Xxxxxxxx 00000
Attention: Xxxxxxx X. Xxxxxxx, General Counsel
Facsimile: (000) 000-0000
with a copy to:
Xxxxxxxx, Xxxxxxxx & Xxxxxx, P.A.
000 X. Xxxxx Xxxxxx, Xxxxx 0000
Xxxxxxxxx, Xxxxx Xxxxxxxx 00000
Attention: Xxxxxxx X. Xxxxx
Xxxxxxx X. Xxxxxxxxx
Xxxxx X. Xxxxx
Facsimile: (000) 000-0000
67
If to CIMA, to:
CIMA LABS INC.
00000 Xxxxxx Xxxx Xxxx
Xxxx Xxxxxxx, Xxxxxxxxx 00000-0000
Attention: Xxxxxx X. Xxxxxx, Chief Executive Officer
Facsimile: (000) 000-0000
with a copy to:
Xxxxxx & Xxxxxxx LLP
000 Xxxx Xxxxxx Xxxxx, Xxxxx 0000
Xxxx Xxxx, Xxxxxxxxxx 00000-0000
Attention: Xxxxxxx X. Xxxxxx
Xxxxxxx X. Xxxx
R. Xxxxx Xxxxx
Facsimile: (000) 000-0000
9.07 Entire Understanding; No Third Party Beneficiaries. This Agreement
represents the entire understanding of the parties hereto regarding the
transactions contemplated hereby and supersede any and all other oral or written
agreements previously made or purported to be made, other than the
Confidentiality Agreement, which will survive the execution and delivery of this
Agreement. No representation, warranty, inducement, promise, understanding or
condition not set forth in this Agreement has been made or relied on by any
party in entering into this Agreement. Except for Section 6.10, which is
intended to benefit the Indemnified Parties to the extent stated, nothing
expressed or implied in this Agreement is intended to confer any rights,
remedies, obligations or liabilities upon any Person other a party to this
Agreement.
9.08 Severability. If any provision of this Agreement or the
application thereof to any Person (including the officers and directors of
aaiPharma or CIMA) or circumstance is determined by a court of competent
jurisdiction to be invalid, void or unenforceable, the remaining provisions, or
the application of such provision to Persons or circumstances other than those
as to which it has been held invalid or unenforceable, will remain in full force
and effect and will in no way be affected, impaired or invalidated thereby, so
long as the economic or legal substance of the transactions contemplated hereby
is not affected in any manner materially adverse to any party. Upon such
determination, the parties will negotiate in good faith in an effort to agree
upon a suitable and equitable substitute provision to effect the original intent
of the parties. Prior to the termination of this Agreement in accordance with
its terms, the absence of a vote, approval or adoption by the stockholders of
aaiPharma or CIMA will not render invalid or inoperative any provision hereof
not specifically required to be contained in the plan of merger to be adopted by
such stockholders pursuant to the applicable provisions of the DGCL.
9.09 Submission to Jurisdiction; Waivers. Each party hereto irrevocably
agrees that any legal action or proceeding with respect to this Agreement or for
recognition and enforcement of any judgment in respect hereof brought by any
party hereto or its successors or assigns may be brought and determined in the
Chancery or other Courts of the State of
Delaware, and each party hereby
irrevocably submits with regard to any such action or proceeding for itself and
in respect
68
to its property, generally and unconditionally, to the nonexclusive jurisdiction
of the aforesaid courts. Each party hereto hereby irrevocably waives, and agrees
not to assert, by way of motion, as a defense, counterclaim or otherwise, in any
action or proceeding with respect to this Agreement, (a) any claim that it is
not personally subject to the jurisdiction of the above-named courts for any
reason other than the failure to lawfully serve process, (b) that it or its
property is exempt or immune from jurisdiction of any such court or from any
legal process commenced in such courts (whether through service of notice,
attachment prior to judgment, attachment in aid of execution of judgment,
execution of judgment or otherwise), or (c) to the fullest extent permitted by
applicable law, that (i) the suit, action or proceeding in any such court is
brought in an inconvenient forum, (ii) the venue of such suit, action or
proceeding is improper or (iii) this Agreement, or the subject matter hereof,
may not be enforced in or by such courts.
9.10 Enforcement. The parties agree that irreparable damage would occur
in the event that any of the provisions of this Agreement were not performed in
accordance with their specific terms. It is accordingly agreed that the parties
shall be entitled to specific performance of the terms hereof, this being in
addition to any other remedy to which they are entitled at law or in equity.
9.11 Acknowledgment. EACH PARTY HERETO ACKNOWLEDGES AND AGREES THAT ANY
CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE
COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE IT HEREBY IRREVOCABLY AND
UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF
ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS
AGREEMENT AND ANY OF THE AGREEMENTS DELIVERED IN CONNECTION HEREWITH OR THE
TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. EACH PARTY HERETO CERTIFIES AND
ACKNOWLEDGES THAT (A) NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY PARTY HERETO
HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH PARTY WOULD NOT, IN THE EVENT
OF LITIGATION, SEEK TO ENFORCE EITHER OF SUCH WAIVERS, (B) IT UNDERSTANDS AND
HAS CONSIDERED THE IMPLICATIONS OF SUCH WAIVERS, (C) IT MAKES SUCH WAIVERS
VOLUNTARILY, AND (D) IT HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG
OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 9.11.
9.12 Assignment. Neither this Agreement nor any of the rights,
interests or obligations hereunder shall be assigned by any of the parties
hereto, in whole or in part (whether by operation of Law or otherwise), without
the prior written consent of each other party hereto, and any attempt to make
any such assignment without such consent shall be null and void.
[THE NEXT PAGE IS THE SIGNATURE PAGE]
69
IN WITNESS WHEREOF, each of the parties have caused this Agreement to
be executed by its duly authorized officer as of the day and year first above
written.
AAIPHARMA INC.
By: /s/ Xxxxxx X. Xxxxxxxx
----------------------------
Name: Xxxxxx X. Xxxxxxxx
Title: President and Chief
Executive Officer
S-1
CIMA LABS INC.
By: /s/ Xxxxxx X. Xxxxxx
----------------------------
Name: Xxxxxx X. Xxxxxx
Title: Interim Chief
Executive Officer
S-2
SCARLET HOLDING CORPORATION
By: /s/ Xxxxxx X. Xxxxxxxxx
----------------------------
Name: Xxxxxx X. Xxxxxxxxx
Title: President
CRIMSON MERGERCO, INC.
By: /s/ Xxxxxx X. Xxxxxxxxx
----------------------------
Name: Xxxxxx X. Xxxxxxxxx
Title: President
SCARLET MERGERCO, INC.
By: /s/ Xxxxxx X. Xxxxxxxxx
----------------------------
Name: Xxxxxx X. Xxxxxxxxx
Title: President
S-3
